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Abbreviations 
ADEM   acute disseminated encephalomyelitis  
 
APCs  antigen-presenting cells 
 
AQP4  aquaporin-4 
 
BCR   B cell receptor 
 
CIS  clinically isolated syndrome  
 
CNS   central nervous system 
 
CSF  cerebrospinal fluid 
 
EAE   experimental autoimmune encephalomyelitis 
 
EBV  Epstein-Barr virus 
 
ELISA  enzyme-linked immunosorbent assay 
 
ELISpot enzyme-linked immunospot 
 
FACS  fluorescence-activated cell sorting   
 
HA  influenza hemagglutinin 
 
IgG  immunoglobulin G 
 
KIR4.1  inward-rectifying potassium channel 4.1 
 
LCMV  lymphocytic choriomeningitis virus  
 
MHC  major histocompatibility complex 
 
MOG  myelin oligodendrocyte glycoprotein 
 
MS   multiple sclerosis 
 
NMO  neuromyelitis optica 
 
OCBs  oligoclonal bands 
 
RIS  radiological isolated syndrome 
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Summary 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous 
system (CNS). Although neither the cause nor the pathomechanism of MS is fully understood, it 
is believed to be caused by autoimmune destruction of the myelin. Various findings in patients 
with MS suggest the involvement of B cells in the pathogenesis. The most prominent finding is 
the presence of oligoclonal bands in patients with MS and the success of B cell depleting 
therapies. Despite tremendous efforts, the target antigens of B cells in MS have not yet been 
identified.  
The goal of our first study (Results I of Part I of the presented work), was to develop a sensitive 
method for identifying antigen-specific B cells in humans, with the future goal of being able to 
identify autoantigen-specific B cells in MS patients. However, in many patients we do not know 
the specific antigens involved, and we expect the frequency of autoreactive B cells to be low. 
Thus, in order to develop a method for isolating such B cells we needed a model in which the 
target antigen is known and B cells specific for that antigen are present in normal human donors. 
Influenza hemagglutinin (HA) was chosen as an appropriate model antigen since healthy 
individuals are commonly immunized against influenza and the frequency of influenza-specific 
B cells is relatively high following immunization. Our method is based on culturing human B cells 
with fluorescently labeled hemagglutinin-expressing cells, followed by a FACS-sort to isolate 
putatively hemagglutinin-specific B cells from other B cells. With this method we were able to 
enrich hemagglutinin-specific B cells approximately 150-fold, as shown by ELISpot. We EBV-
transformed FACS-sorted B cells to enable the production of monoclonal antibodies needed for 
the analysis of the B cell specificity. The transformations with EBV were performed with B cells 
from four different donors by adding 30-60 sorted B cells per well, yielding transformed B cell 
colonies in 48-75% of wells. Antibodies in the supernatants from those cultures were examined 
for their binding capacity to HA. Between 15% and 26% of GFP-capturing B cell cultures, and 
between zero and 3% of non-capturing B cell cultures produced antibodies that showed binding 
to HA by ELISA. By a cell-based flow cytometric assay 2.7-26% of GFP-capturing B cell cultures 
and none of the non-capturing B cell cultures produced antibodies that showed binding to HA. In 
addition, FACS-sorted B cells were subjected to an in vitro expansion protocol that also allowed 
the recombinant expression of immunoglobulins. Seventy-two combinations of heavy and light 
chains were expressed recombinantly and the cloned antibodies were tested by IgG ELISA for 
binding to HA, tetanus toxoid, BSA and anti-IgG. Of those 72 combinations, 42 showed binding 
to HA and 5 showed polyspecific binding to BSA, tetanus or both, in addition to HA.
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Because this method isolates intact cells, rather than soluble antibodies, it can be used for the 
identification of B cells whose B cell receptor (BCR) is specific for unknown antigens, e.g. 
antigens expressed on the myelin sheath but of unknown identity.  
In a connected project that also makes use of the phenomenon of membrane capture by B cells 
(Results II of Part I of the presented work), we tested a novel hypothesis of B cell autoimmunity 
in an in vitro system. We examined whether B cells induce autoimmunity indirectly by activating 
autoreactive T cells via the following mechanism: a B cell binds and captures its cognate antigen 
from an antigen-expressing cell, and simultaneously captures other membrane components 
including self-antigens. The possibility arises that this B cell, in parallel with processing its 
cognate antigen, processes and presents this "bystander antigen" to T cells of the appropriate 
specificity, which in an inflammatory context would induce a self-destructive T cell response. We 
tested this hypothesis using adherent cells that express the CNS-restricted membrane protein 
myelin oligodendrocyte glycoprotein (MOG) as a model self-antigen, influenza hemagglutinin 
(HA) as a model viral antigen, and transgenic mouse B and T cells specific for each antigen. 
This antigen pair was chosen because both are integral membrane proteins, with a plausible 
role in autoimmunity. MOG is implicated in autoimmune neurological disorders and animal 
models thereof, notably in acute demyelinating encephalomyelitis, and influenza is among the 
most important known viral triggers of this autoimmune condition. In our study we observed the 
following two mechanisms: (i) cognate antigen is rapidly captured from membranes and induces 
strong activation of the capturing B cell and (ii) smaller quantities of other co-expressed, 
"bystander" antigens are co-captured at the same time and can be presented to T cells as well. 
This non-cognate antigen co-capture was observed in two different paradigms. HA-specific 
B cells co-capture MOG and present it to autoreactive MOG-specific T cells; and MOG-specific 
B cells co-capture a fusion protein of HA and ovalbumin and present it to ovalbumin-specific 
T cells. The fusion protein was generated because HA-specific T cells were not available. This 
phenomenon thus has two kinds of implications for autoimmunity: viral antigen-specific B cells 
can activate self-reactive T cells, and conversely, self-antigen-specific B cells can receive T cell 
help from virus-specific T cells, leading to the production of autoantibodies. These findings offer 
a possible explanation for the link between autoimmunity and viral infections. 
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Introduction 
Multiple sclerosis – a demyelinating disease 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system 
(CNS). It is the most common disabling neurological disorder in young adults. The onset typically 
occurs between the ages of 20-40 years, and women are about 2 times more likely to develop 
MS than men [1]. Although the origin of MS is unknown, it is believed to be caused by 
autoimmune destruction of the myelin [2]. Myelin coats, protects and insulates nerves of both the 
central and the peripheral nervous system, enabling them to quickly conduct impulses between 
the brain and different parts of the body. The destruction of myelin, axons and neurons in the 
central nervous system is what causes many of the signs and symptoms of MS [3,4]. 
Symptoms and their severity may differ significantly from patient to patient, and over the course 
of the disease, depending on the location of affected nerve fibers and severity of the damage. 
MS is typically diagnosed based on presenting symptoms like vision and balance problems, 
dizziness, fatigue, bladder problems and stiffness and/or spasms in combination with supporting 
magnetic resonance imaging and laboratory testing [5]. The most commonly used criteria for 
diagnosing MS are the McDonald criteria, which focus on clinical, laboratory, and radiologic 
evidence of demyelinating lesions at different time points and affecting different areas of the 
CNS [6,7]. Treatment of MS typically focuses on speeding recovery from relapses, slowing down 
the inflammatory activity and managing MS signs and symptoms. Medications used in MS can 
reduce the frequency and severity of relapses as well as the development of new lesions in the 
brain, but they do not cure MS [8]. 
Four different major clinical subtypes of MS have been defined: relapsing-remitting, secondary 
progressive, primary progressive, and progressive-relapsing MS [9]. Relapsing-remitting MS is 
characterized by clearly defined, often unpredictable relapses followed by periods of weeks to 
years of remission, in which patients are clinically stable. This subtype is the most common form 
of the disease. The majority of patients with MS begin with a relapsing-remitting course and this 
stage can last for years or even decades. Secondary progressive MS occurs in patients with 
an initial relapsing-remitting disease course followed by progression with or without occasional 
relapses, minor remissions, and plateaus. In primary progressive MS, patients show a 
progression of disability from onset with occasional periods of exacerbation and remission. 
Although modest fluctuations in neurological disability may be seen, those patients do not 
experience relapses. In progressive-relapsing MS, which is the least common disease course, 
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patients show a progression of disability from onset but with occasional relapses. The periods 
between relapses are characterized by a continuous progression [9]. In 2013, an international 
panel reviewed these definitions by adding two new disease subtypes; clinically isolated 
syndrome (CIS) and radiological isolated syndrome (RIS) [10]. CIS is defined as first clinical 
presentation of a disease that could be MS, showing characteristics of inflammatory 
demyelination, but which yet has to fulfill criteria of dissemination in time [11]. In RIS the 
situation is more complicated. Incidental imaging findings suggest an inflammatory 
demyelination but clinical signs or symptoms are not present in the patient [12]. Although these 
definitions of the disease courses exist, and they are relevant for prognosis and treatment 
decisions, it should be noted that the course of MS in an individual patient is widely 
unpredictable. 
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The role of B cells in multiple sclerosis   
It has long been speculated that MS is a disease mediated by myelin-reactive T cells. Evidence 
supporting this hypothesis includes the observations that MS is characterized by recruitment of 
activated T cells into the CNS [13] and that T cells outnumber B cells in MS lesions [14,15]. 
Furthermore, T cells play an important role in the most used animal model of MS, i.e., 
experimental autoimmune encephalomyelitis (EAE). Inflammatory demyelinating disease can be 
induced in mice by adoptive transfer of activated, encephalitogenic, myelin-specific T cells [16]. 
Interest in the role of B cells in EAE was initially limited to their ability to produce antibodies that 
could mediate demyelination [17]. 
In the past few years, the concept of MS being a T cell mediated autoimmune disease has been 
challenged, and the role of B cells reassessed [18,19]. It has been reported that under 
physiological conditions in healthy people, the frequency of B cells, plasmablasts, and plasma 
cells in cerebrospinal fluid (CSF), is rather low, contrary to the CSF of patients with MS, which 
shows an increase in B cells reaching up to 5% of all mononuclear cells therein. The ratio of 
B cells to monocytes correlates with disease progression and a higher B cell count indicates a 
more aggressive course of the disease [20]. 
The presence of oligoclonal bands (OCBs) in the CSF is the most consistent immunological 
finding in patients with MS and similarly one of the few biomarkers used in clinical practice for 
the establishment of the diagnosis of MS [21,22]. OCBs arise from the intrathecal synthesis of 
clonal IgG. These clonally expanded antibodies seem to be stable over a long period of time and 
are found specifically in the CSF but not in serum of more than 95% of patients with MS [23,24]. 
Many attempts have been made to find the target antigens of these OCBs but yet none could 
successfully be identified. In addition to that, recombinant monoclonal antibodies cloned from 
human B cells in CSF, failed to show binding to well known myelin antigens or to brain 
sections [25].  
More evidence for an important role of B cells in MS is supported by the remarkable success of 
B cell depleting therapies. One of the most meaningful changes in MS therapy was reached 
through the development of monoclonal antibodies. Several different, tested molecules promise 
to show a higher therapeutic efficacy than currently available baseline treatments like interferons 
[26]. Although the target antigens of these therapeutic antibodies are known, there are still 
uncertainties about which exact mode of action is responsible for their therapeutic effect, since 
these antibodies target a wide range of immune cells. The humanized monoclonal antibody 
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natalizumab for example, blocks the α4 subunit of the VLA-4 receptor that is expressed on most 
leukocytes and which is needed for migration across the blood-brain barrier [27]. Alemtuzumab, 
another monoclonal antibody effective in treating MS, is known to deplete all cells expressing 
the CD52 molecule, including not only B cells, but also T cells, natural killer cells, dendritic cells, 
most monocytes and macrophages [28]. Rituximab, which is interestingly the only cell-type-
specific antibody used in MS, depletes B cells positive for the CD20 antigen. It has shown a high 
efficacy in treating relapsing-remitting MS by reducing the number of gadolinium-enhancing 
lesions and the proportion of patients experiencing relapses [29,30]. CD20 is expressed in 
different stages of B cell differentiation, from pre-B cells to naïve and memory B cells, but is 
absent in earlier stages and plasma cells [31]. The second generation of anti-CD20 molecules, 
like ocrelizumab and ofatumumab, showed similar results in clinical trials [32,33]. The success in 
relapsing-remitting MS of treatments specifically targeting B cells provides not only evidence for 
the pathogenic role of B cells in MS, but enables a possible elucidation of how B cells may be 
acting. Interestingly, anti-CD20 molecules neither target plasma cells nor do they influence IgG 
levels in the CSF or OCBs of patients with MS in the short term, suggesting that the 
autoantibody production of B cells is not what mediates the pathogenesis in MS [34]. 
During the last few years, our understanding of the role of B cells in the pathogenesis of MS has 
progressed tremendously. Although B cells have been known best for their antibody-producing 
function, they are now recognized as main players in conjunction with T cells by acting as 
antigen-presenting or cytokine-producing cells, exhibiting stimulatory, regulatory, as well as pro- 
and anti-inflammatory capacities [35]. The characterization of diverse B cell phenotypes will 
allow further elucidation of the role of B cells in MS and lead to the development of novel 
disease treatment and prevention strategies. 
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The search for autoantigens in demyelinating CNS diseases 
The antigen specificity of B cells is assumed to play a leading role in their antigen-presenting 
and antibody-producing function. What antigen these antibodies may recognize has been 
controversial for years. Compared to T cells, B cells recognize antigens independently of the 
major histocompatibility complex (MHC), which has several consequences. B cells can 
recognize antigens either in solution or located on the surface of cells and quite often they 
recognize epitopes dependent on their native conformation. These characteristics of B cell 
antigen recognition play an important role when antibodies are used to identify target antigens. 
Myelin oligodendrocyte glycoprotein (MOG) has been the focus of extensive research for 
more than thirty years and is probably the best studied B cell antigen in MS [36]. MOG is mainly 
located at the outermost surface of myelin in the CNS, which makes it accessible for antibodies. 
The role of MOG as an autoantigen for T cells and as a target of demyelinating antibodies has 
been established in various forms of EAE [37]. However, the role of MOG antibodies in human 
MS is more controversial. Although MOG antibodies can neither be used for the diagnosis of MS 
nor for the prediction of the course of the disease [38], they have recently been shown to be 
associated with pediatric demyelinating disease [39,40]. Antibodies against MOG could be 
detected in around one quarter of pediatric patients with MS or acute disseminated 
encephalomyelitis (ADEM) and were shown to correlate with the course of the disease. The 
presence of MOG antibodies in these children was strongly negatively correlated with age, 
which interestingly could indicate that the myelination process, which is still ongoing at that age, 
influences the autoantigenic response [41].  
Aquaporin-4 (AQP4) was the first specific molecule and also the first example of a water 
channel which has been identified as a target for the autoimmune response in CNS 
demyelinating diseases. AQP4 is the most prominent B cell target in neuromyelitis optica (NMO). 
Its discovery contributed tremendously to the understanding of this disease. Anti-AQP4 
antibodies constitute a highly specific marker of NMO. An additional characteristic which enables 
differentiation between NMO and MS is the specific loss of AQP4 expression in lesions [42]. The 
first relevance of anti-AQP4 antibodies was demonstrated by staining brain slices with sera from 
patients with NMO [43,44]. Further significance was shown in an animal model of NMO, in which 
recombinant anti-AQP4 antibody or anti-AQP4 antibody-containing sera were transferred into 
animals, resulting in pathological changes resembling this disease [45,46]. 
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Recently, the detection of autoantibodies against the inward-rectifying potassium channel 4.1 
(KIR4.1) was described as a possible breakthrough in understanding the pathophysiology of 
MS. In 2012, Srivastava and colleagues identified anti-KIR4.1 antibodies in sera of MS patients 
by immunoprecipitation of human brain proteins and reported that over 40% of patients with MS 
harbor these antibodies in serum, compared to less than 1% of the controls [47]. Several 
subsequent independent studies have failed to reproduce this finding [48,49], presumably 
because they relied on a peptide ELISA wherease the original study used a protein ELISA to 
detect anti-KIR4.1 antibodies. However, the most recent study by Pröbstel and colleagues was 
performed with an identical method as originally described and neither the KIR4.1 protein nor 
the peptide ELISA distinguished patients with MS from controls [50].  
The search for autoantigens in MS is still an open field of research. The discovery of disease-
specific autoantibodies against AQP4 and MOG, as B cell targeted autoantigens, has enabled a 
big step towards autoantigen-targeted therapies. Hopefully more autoantibodies will be 
discovered that are clinically useful for diagnosis and stratification of patients with MS.  
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Antigen capture by B cells 
While the uptake of soluble antigen by B cells has been known for decades, only a few years 
ago it was reported that B cells can capture antigens also when expressed on membranes. In 
2006, Fleire and colleagues observed using live cell imaging that B cells capture antigens by 
spreading over a solid substrate, followed by an internalization of the BCR-antigen complex and 
a rounding and retraction of the B cell. Furthermore, they demonstrated that subsequently these 
B cells can present these captured antigens to T cells. The T cell activation was monitored by 
measuring interleukin-2 production after 24 hours [51].  
In 2013, Natkanski and colleagues reported on the mechanical energy B cells use to 
discriminate antigen affinities. They developed an experimental model for studying immune 
synapses using immobilized plasma membrane sheets and planar lipid bilayers. B cells 
interacting with plasma membrane sheets including cognate antigen captured not just the 
antigen, but large pieces of membrane with it. By contrast, B cells that formed synapses with 
planar lipid bilayers did not take up any antigen or membrane pieces, suggesting that B cells 
require flexibility of the presenting membranes to pinch off the antigen together with pieces of 
the membrane. The authors suggested that a similar phenomenon occurs when B cells interact 
with cells expressing their cognate antigen, i.e., the B cell captures both the antigen and 
significant amounts of membrane [52].  
Another approach, by Beadling and Slifka, describes a method to quantify T cells without 
knowing the fine epitope specificity. The method is based on biotinylation and streptavidin-
fluorochrome labeling of antigen-presenting cells (APCs), followed by subsequent acquisition of 
this label by antigen-specific T cells. They used splenocytes from mice that were immunized with 
lymphocytic choriomeningitis virus (LCMV) or splenocytes from naïve mice. After mixing 
splenocytes with peptide-pulsed APCs, they labeled the LCMV-specific T cells with MHC 
tetramers and by intracellular cytokine labeling before subjecting to flow cytometry to examine 
CD8+ T cells. The small population of antigen-specific T cells identified by tetramer labeling and 
antigen-dependent cytokine production was almost identical to the population identified by 
acquisition of fluorochrome from the APCs [53]. The goal of the first part of the presented work 
(Results I of Part I) was to adapt this method for B cells. 
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Aim of the Thesis 
In the first part of the presented work (Results I of Part I) we aimed to generate a method to 
identify human antigen-specific B cells recognizing membrane-bound, complex antigens in their 
real conformation. The identification of B cells specific for particular antigens has shown to be 
difficult because of their unknown, presumably very low frequency. In the last thirty years, 
different techniques have been established to isolate antigen-specific B cells that recognize 
conformational epitopes, most of them using antigens in their soluble form. However, in some 
cases it is impossible to mimic a real conformation using soluble antigens. Autoimmune 
antibodies in myasthenia gravis for example bind to acetylcholine-receptors consisting of 
membrane-protein clusters. At present, no technique exists to isolate B cells that recognize such 
membrane-bound, complex antigens. Therefore, we aimed in the first part of this work at filling 
this gap by generating a technique enabling the identification and isolation of exactly these 
B cells. In a next step we aimed to characterize these isolated B cells and confirm their antigen-
specificity by different read-outs, i.e., ELISpot, ELISA and a cell-based flow cytometric assay.  
In the second part of the presented work (Results II of Part I) we tested a novel hypothesis 
linking B cells, viral infection and autoimmunity. It has been known for decades that B cells can 
specifically capture, process and present antigens that are recognized by their B cell receptors. 
The antigen recognized by B cells has been generally considered to be soluble. Recently, it was 
reported that B cells are able to capture their cognate antigens also when expressed on the 
surface of antigen-expressing target cells. It appears that this antigen capture involves not only 
the antigenic molecule itself, but also substantial fragments of the target cell membrane, 
presumably along with numerous other proteins. This led to the question whether B cells can 
induce autoimmunity indirectly by presenting co-captured self-antigens to self-reactive T cells. 
To investigate this hypothesis, we addressed the following three main questions: (i) Can B cells 
capture membrane-bound cognate antigen? (ii) Do they co-capture non-cognate antigens? 
(iii) Do they present both cognate and non-cognate antigens to T cells? We answered these 
questions in an in vitro model using transgenic B and T cells.  
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ABSTRACT 
The identification and isolation of B cells specific for particular antigens is difficult because of 
their very low frequency in peripheral blood. Existing methods to identify antigen-specific cells, 
like rosetting or cell sorting techniques with fluorescent antigens are well developed. However, 
these techniques use recombinant antigens in soluble form, which poses the problem that 
especially complex protein like multichannel proteins may not retain their native conformation. 
There are several examples showing that the native conformation of the antigen is essential for 
recognition of antibodies since these antibodies recognize conformational rather than linear 
epitopes. The aim of this newly developed assay was to retain the native conformation of the 
target antigen used for isolating specific B cells. 
Using influenza hemagglutinin as a model we have established a sensitive technique for 
isolating intact, living B cells recognizing their cognate antigens in cell membranes in their native 
conformation. The technique is based on culturing human B cells from peripheral blood for 
several hours with adherent cell lines expressing a fusion protein of hemagglutinin and GFP, to 
allow GFP-antigen uptake. GFP-capturing B cells get FACS-sorted and analyzed for their 
antigen-specificity by ELISpot, ELISA and cell-based flow cytometric assays. A subsequent 
immortalization of GFP-capturing B cells by Epstein-Barr virus or alternatively in vitro expansion 
of GFP-sorted B cells enabled us to get single B cell clones to reconstruct recombinant 
antibodies. 
With this novel and sensitive technique we were able to significantly enrich hemagglutinin-
specific B cells and confirm their specificity by different read-outs. We believe that this technique 
will also be applicable to identify B cells directed against membrane associated tumor antigens 
or autoantigens.  
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INTRODUCTION 
Antibodies have made a dramatic transformation from valuable scientific tools in research to 
powerful therapeutics introduced in the clinic [1]. One of the current largest growing fields are 
antibody biopharmaceuticals used as treatment against cancer or autoimmune diseases [2]. A 
key for understanding how antibodies recognize their target antigen is the identification of the 
binding site, or epitope. Epitopes are commonly divided into two categories, linear epitopes and 
conformational epitopes. Antibodies often recognize conformational epitopes in which key amino 
acid residues are brought together by protein folding, rather than linear epitopes where a stretch 
of continuous amino acids is sufficient for binding [3].  
Production of useful antibodies generally depends on the isolation of B cells recognizing a 
particular antigen, but the identification of B cells that are specific for any given antigen is difficult 
because of their very low frequency. It has been reported that the frequency of B cells specific 
for any particular antigen is usually less than 1% [4,5]. Another difficulty is the lack of 
appropriate markers to evaluate the purity of the isolated cells. 
Common techniques to identify antigen-specific B cells like cell sorting techniques involving 
staining with fluorescent antigens quite often use antigens in their soluble forms, which makes 
those techniques unsuitable for antigens that form their real conformation only in a membrane-
bound state. B cells, which only recognize such conformation-dependent protein antigens, will 
not be identified by existing methods. Examples of conformation-dependent B cell recognition 
include viral envelope proteins (it is known that at least some broadly neutralizing antibodies do 
not bind to linear epitopes [6]), and autoreactive B cells in myasthenia gravis that recognize 
acetylcholine-receptors consisting of membrane-proteins densely packed in relatively immobile 
clusters [7].  
While the uptake of soluble antigen by B cells has been known for decades, it has only recently 
been reported that B cells can capture antigens also from membranes of other cells. Fleire and 
colleagues observed using live cell imaging that B cells capture antigens by spreading over a 
solid substrate, followed by an internalization of the BCR-antigen complex and a rounding and 
retraction of the B cell. They demonstrated that subsequently these B cells can present the 
captured antigens to T cells [8]. Natkanski and colleagues reported on the mechanical energy 
B cells use to discriminate antigen affinities. By comparing immobilized plasma membrane 
sheets and planar lipid bilayers as an experimental model for studying immune synapses, they 
concluded that B cells require flexibility of the presenting membranes in order to pinch off the
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antigen together with pieces of the membrane [9]. To isolate B cells, which recognize 
membrane-proteins, we postulated that it ought to be possible to develop a method based on 
this phenomenon of membrane capture.  
Beadling and Slifka described a method to quantify T cells without knowing the fine epitope 
specificity, based on biotinylation and streptavidin-fluorochrome labeling of antigen-presenting 
cells, followed by subsequent acquisition of this label by antigen-specific T cells. The small 
population of antigen-specific T cells identified by tetramer labeling and antigen-dependent 
cytokine production was almost identical to the population identified by acquisiton of 
fluorochrome from the APCs [10]. In our study we tried to adapt this method for B cells.  
Using influenza hemagglutinin as a model antigen we aimed to develop a novel and sensitive 
technique for isolating intact, living B cells recognizing their cognate antigens in membrane-
expressed form in their native conformation. The technique is based on culturing human B cells 
from healthy donors for several hours with an adherent cell line expressing a fusion protein of 
hemagglutinin and GFP, to allow GFP-antigen uptake. By FACS-sorting of GFP-capturing 
B cells we tried to enrich them and analyse their specificity by ELISpot, ELISA and cell-based 
flow cytometric assays.  
 
MATERIALS AND METHODS 
Plasmids and cell lines 
Cloning:  
A plasmid encoding influenza hemagglutinin A/California/04/09 amino acids 1-529 (GenBank: 
ACP41105.1) was purchased from Sino Biological (Beijing, China, cat no. VG11055-C), the 
open reading frame was amplified and fused to an oligonucleotide (purchased from Microsynth, 
Balgach, Switzerland) encoding amino acids 530-566. To incorporate the tyrosine-to-
phenylalanine mutation (Y98F) in the sialic acid binding site of hemagglutinin (HA) [11], the 1-
529 amplicon was generated in two segments, with overlaps including the target residue, 
enabling us to include the mutation in the primers, and then all three sections (corresponding to 
amino acids 1-98, 99-529, and 530-566) were joined by template switching PCR and cloned into 
the PigLIC vector which confers puromycin (Gibco) resistance. To make the plasmid encoding 
the fusion protein HA-Y98F-GFP, we amplified GFP from pcDNA6.2C-EmGFP-DEST 
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(Invitrogen) and fused it to the mutated HA construct described above between amino acid 566 
and the STOP codon.  
To generate a plasmid coding for the fusion protein MOG-GFP, the open reading frame 
encoding amino acids 1-204 of rat MOG (UniProt: Q63345.1) was amplified from pRSV-MOG (a 
kind gift from Nicole Schaeren-Wiemers, University of Basel, Switzerland), and GFP amplified 
from pcDNA6.2C-EmGFP-DEST (Invitrogen) was added at the carboxyl terminal, before cloning 
into PigLIC. Accuracy of plasmid sequences after cloning was verified by sequencing. 
Cell lines: 
TE671 rhabdomyosarcoma cells and HEK293 embryonic kidney cells (referred to as “TE cells” 
and “HEK cells” throughout the text) were obtained from ATCC (LGC, Wesel, Germany). Cells 
were cultured in complete RPMI medium or complete DMEM medium (10% heat-inactivated 
fetal calf serum, 100 units/ml of penicillin and 100 ug/ml of streptomycin; all reagents obtained 
from Gibco), at 37°C in 5% carbon dioxide. Cells were tested for mycoplasma infection on arrival 
and subsequently (LookOut Mycoplasma PCR Detection Kit, Sigma Aldrich). Mouse fibroblasts 
stably transfected with human CD40 Ligand (a kind gift from Edgar Meinl, Ludwig-Maximilians-
Universität, Munich, Germany), used as feeder cells for EBV transformation, were cultured in 
complete DMEM medium supplemented with 0.5mg/ml of the selective antibiotic Geneticin 
(G418 Sulfate, cat no. 10131-035, Gibco) at 37°C in 5% carbon dioxide. For irradiation, cells 
were washed once in PBS 1X, trypsinized, resuspended in ice-cold FCS (all reagents obtained 
from Gibco) and kept on ice during the irradiation (75 Gy).  
Transfection: 
TE and HEK cells were transfected by exposure to 0.5 µg/ml of plasmid DNA, 0.75 µg/ml of 
polyethylenimine and 0.125 mg/ml 20% Glucose in complete RPMI medium for six hours. 
Transfection reagent was removed and replaced with 6 ml of complete RPMI medium. The 
appropriate selective antibiotic was added from the following day on. Cells resistant to the 
appropriate selective antibiotic were labeled as described below and sorted by the Department 
of Biomedicine Flow Cytometry Core. 
Verification of transgene expression: 
TE cells expressing influenza A H1N1 hemagglutinin (A/California/04/2009) with or without 
incorporated tyrosine-to-phenylalanine mutation (Y98F) or non-transfected TE cells (referred to 
as “TE wildtype HA”, “TE mutated HA” (TE mHA) and “TE 0” throughout the text) were incubated 
with RM10 antibody (rabbit monoclonal antibody anti-influenza A H1N1 hemagglutinin, cat no.
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11055-RM10, Sino Biological) 1:1000 diluted in flow buffer or human sera from before and after 
influenza vaccination 1:300 diluted in flow buffer for 45 minutes on ice, washed three times with 
cold flow buffer (composed of PBS 1X supplemented with 2% FCS and 0.1% azide), incubated 
with PE-conjugated anti-human IgG or PE-conjugated goat anti-rabbit IgG, each 1:100 diluted in 
flow buffer, on ice for 30 minutes, washed twice in cold flow buffer, and subjected to flow 
cytometry (Attune Flow Cytometer, Applied Biosystems). All centrifugation steps were at 300 g, 
for 5 minutes at 5°C. DAPI (Sigma Aldrich) was added at 200 ng/ml to enable exclusion of dead 
cells.  
Mice and primary immune cells 
C57Bl/6 mice were bred in the University of Basel Mouse Core Facility. IgHMOG mice were a kind 
gift from Guru Krishnamoorthy and Hartmut Wekerle (Max-Planck-Institut für Neurobiologie, 
Martinsried, Germany). Primary immune cells were obtained from spleens by mechanical 
disruption followed by brief settlement under gravity to remove tissue fragments. B cells were 
obtained by positive selection using mouse CD19 microbeads from Miltenyi (cat no. 130-052-
201). All procedures involving animals were authorized by the local veterinary office.   
Human samples 
Healthy donors, male and female, between 25 and 65 years old, were vaccinated against the 
seasonal influenza with Agrippal®, containing inactivated influenza virus surface antigens 
(hemagglutinin and neuraminidase) from type A/H1N1 (A/California/2009 (H1N1)pdm09), type 
A/H3N2 and type B. All healthy donors gave written informed consent. Use of human blood 
samples was approved by the local ethics committee (49/06).  
Blood was drawn into S-Monovette tubes (Sarstedt, 7.5ml K3E, REF 01.1605.100, 1.6 mg 
EDTA/ml blood) before the vaccination and 7, 10 or 14 days after vaccination. 15 ml of EDTA-
blood was diluted with an equal volume of PBS 1X (Gibco), carefully layered over 15 ml of Ficoll-
Paque (Axon Lab, Switzerland) in 50 ml conical tubes and centrifuged in a swinging-bucket rotor 
at 600 g for 20 minutes without brake at room temperature. Mononuclear cell layers were 
carefully collected and transferred to new 50 ml conical tubes, washed twice with PBS 1X by 
centrifuging at 270 g for 10 minutes at room temperature and frozen in cryovials in aliquots of 
20-30 million PBMC in 1 ml FCS-10% DMSO (FCS from Gibco, DMSO from Sigma Aldrich). 
Cryovials were immediately transferred into freezing containers containing 100% isopropanol, 
put into -80°C freezer and transferred to liquid nitrogen the next day.  
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Blood for serum was drawn into S-Monovette tubes containing granulate beads with silicate 
clotting activator (Sarstedt, 7.5 ml Z, REF 01.1601.100) and left at room temperature for 30-60 
minutes to allow coagulation, before centrifuging at 2000 g for 10 minutes at room temperature. 
Serum was aliquoted and frozen at -80°C.  
B cell enrichment 
PBMC were quickly thawed in 10 ml pre-warmed complete RPMI medium and put into incubator 
for one hour at 37°C, centrifuged and resuspended in ice-cold separation buffer, counted and 
enriched for B cells by negative selection using biotinylated antibodies and magnetic beads from 
Miltenyi (human B cell Isolation Kit II, cat no. 130-091-151). All spinning steps were at 300 g for 
5 minutes at 5°C. Separation buffer was made by sterile filtering 500 ml PBS 1X (Gibco) 
containing 0.5% BSA (Sigma Aldrich) and 2 mM EDTA.  
FACS isolation of putatively hemagglutinin-specific B cells 
B cells were isolated from PBMC after influenza vaccination, co-cultured for three hours with 
CTV-labeled TE mHA-GFP cells, retrieved and incubated with PerCP-Cy5.5-conjugated anti-
human CD19 (for IgG ELISpot experiments) diluted 1:20 in cold separation buffer or with APC-
conjugated anti-human CD45 (for EBV transformation experiments and high-throughput B cell 
activation) diluted 1:50 in cold separation buffer. Cells were gated on scatter to select live, single 
cells; on CD19high or CD45high to exclude contaminating TE cells; and two subgates were used 
for sorting (FACSAria III Cell Sorter, BD Biosciences): “GFP-capturing”, i.e., GFP-positive, CTV-
low-to-intermediate; and “GFP-non-capturing”, i.e., GFP-negative, CTV-low.  
ELISpot for detection of HA-specific, IgG-secreting human B cells 
Human IgG B cell ELISpot kit was obtained from Mabtech, Sweden (Code: 3850-2A). Plates 
were coated according to the provided protocol with hemagglutinin at 5 ug/ml, or anti-IgG 
capture-antibody (provided with the kit) at 15 ug/ml, or bovine serum albumin at 5 ug/ml. Plates 
were washed with 200 ul/well sterile PBS 1X and blocked with 100 ul/well complete RPMI 
medium, according to the provided protocol. B cells were isolated from PBMC from after 
influenza vaccination, co-cultured for three hours with TE mHA-GFP and labeled with anti-
human CD19. GFP-capturing and non-capturing CD19-positive B cells were sorted into ELISpot 
plate containing 200 ul/well complete RPMI medium supplemented with 1 ug/ml R848 and 10 
ng/ml recombinant human IL-2 (both provided with the kit). After incubating for three days at 
37°C in 5% carbon dioxide, the plates were washed five times with 200 ul/well PBS 1X and 
developed by incubating with biotinylated anti-human IgG, followed by streptavidin-AP and 
BCIP/NBT substrate solution to visualize IgG-specific spots. All antibodies and solutions were
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provided with the kit and all steps were performed according to the protocol. Plates were 
analyzed by AID ELISpot reader (AID, EliSpot Reader, software version 7.0, build 14790, AID 
GmbH, Ebinger Strasse 4, 72479 Strassberg, Germany). Results were shown as number of 
counted spots and the corresponding overall spot area in mm2. 
EBV transformation of FACS-isolated hemagglutinin-specific B cells 
GFP-capturing and non-capturing B cells were sorted into 1.5 ml Eppendorf tubes containing 
200 ul complete RPMI medium, mixed gently with 500 ul of pre-warmed EBV supernatant 
(ATCC-VR-1492 Epstein-Barr virus, strain B95-8) and incubated for one hour at 37°C in 5% 
carbon dioxide. Flat-bottom 96WP were prepared containing 30,000 irradiated CD40L mouse 
fibroblasts in RPMI medium containing 20% non-heat-inactivated fetal calf serum, 100 units/ml 
of penicillin, 100 ug/ml of streptomycin and 1ug/ml of TLR agonist R848 (Mabtech, Sweden, 
REF 3611-5X), referred to as “RPMI-20” throughout the text. B cells were added to plates at 30 
cells per well and incubated for at least two weeks at 37°C in 5% carbon dioxide.  
Proteins, antibodies and vital dyes 
Bovine serum albumin (cat no. A4503) was obtained from Sigma Aldrich. Influenza A H1N1 
hemagglutinin (A/California/04/2009) protein (cat no. 11055-V08B) and rabbit monoclonal anti-
HA antibody RM10 (cat no. 11055-RM10) was both obtained from Sino Biological (Beijing, 
China).  
PerCP-Cy5.5 anti-human CD19 (clone HIB19, BD Biosciences, cat no. 561295), BV510 anti-
human CD20 (clone 2H7, BD Biosciences, cat no. 563067), APC anti-human CD45 (clone HI30, 
BD Pharmingen, cat no. 555485), PerCP-Cy5.5 anti-mouse CD69 (clone H1.2F3, Biolegend, cat 
no. 104521), APC-Cy7 anti-mouse B220 (clone RA3-6B2, BD Biosciences, cat no. 552094), PE 
anti-human IgG (Jackson Immunoresearch, cat no. 109-116-098), Alexa Fluor 488 anti-human 
IgM (Jackson Immunoresearch, cat no. 109-545-129), PE anti-rabbit IgG (Jackson 
Immunoresearch, cat no. 111-116-144). Anti-human IgG/HRP (cat no. P0214) and anti-human 
IgM/HRP (cat no. P0215) both obtained from Dako.  
Cell Trace Violet was obtained from Thermo Fischer Scientific (cat no. C34557) and DAPI from 
Sigma Aldrich.  
Flow cytometric antibody assay 
For each supernatant, 100 ul of flow buffer containing 50,000 each of unlabeled TE mHA and 
CTV-labeled TE 0 cells were mixed and incubated with 25 ul of supernatant from EBV 
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transformed B cell clones for 30 minutes on ice, washed three times with cold flow buffer, 
labeled with PE-conjugated anti-human IgG and Alexa Fluor 488-conjugated anti-human IgM for 
20 minutes on ice, washed twice with cold flow buffer and subjected to flow cytometry. 
ELISA  
96WP from Corning (Costar 3590 96well EIA/RIA plate flat bottom without lid) were used. Bovine 
serum albumin and Tween were both obtained from Sigma Aldrich, PBS 1X from Gibco, TMB for 
chromogenic development from KPL (SureBlue RESERVE, TMB Microwell Peroxidase, 53-00-
00) and 1N hydrochloric acid from Acros Organics. 
Plates were coated with hemagglutinin and BSA, each at 5 µg/ml, overnight at 4°C on the 
shaker. Plates were washed three times with 250 µl/well PBS-0.05% Tween and blocked with 
100 µl/well PBS-2%BSA at room temperature for two hours on the shaker. Supernatants from 
FACS-isolated, EBV-transformed, putatively hemagglutinin-specific B cell clones, and from GFP-
non-capturing, putatively non-hemagglutinin-specific, negative control B cell clones, were diluted 
1:3 in PBS-0.5%BSA. Plates were incubated with diluted supernatants for two hours at room 
temperature on the shaker, washed three times with 250 µl/well PBS-0.05% Tween and 
incubated with rabbit anti-Human IgG HRP (1:6000 diluted) or rabbit anti-human IgM HRP 
(1:1000 diluted) in PBS-0.5% BSA for one hour at room temperature on the shaker. Plates were 
washed three times with 250 µl/well PBS-0.05% Tween and developed with 100 µl/well (pre-
equilibrated to room temperature) TMB until a blue color was visible. The reaction was stopped 
with 100 µl/well 1N HCl and the plates read at 450 nm immediately after stopping.  
High-throughput B cell in vitro expansion and ELISA  
High-throughput B cell activation and supernatant screening by ELISA was performed according 
to the method published by Huang and colleagues in 2013 [12]. 
FACS-isolated, GFP-capturing and non-capturing B cells were plated at approximately 1.6 cells 
per well into 384WP wells containing IL-2, IL-21 and irradiated mouse CD40L cells to induce 
activation and expansion of the B cells. After 12 days, supernatants from these B cell clones 
were assayed as described above (see ELISA section) with the addition of tetanus toxoid coated 
wells as negative controls and anti-IgM and anti-IgG capture antibody-coated wells as positive 
controls.
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Generation of recombinant monoclonal antibodies  
The cDNA encoding heavy and light chains were cloned from 35 GFP-capturing B cell cultures 
producing anti-HA antibodies, and expressed recombinantly using standard methods.  
Assessment of cell membrane protein transfer to human B cells 
TE mHA and TE 0 cells were biotinylated (EZ-Link Sulfo-NHS-Biotin, Thermo Scientific, cat no. 
21326), plated into 6WP at 300,000 cells per well in complete RPMI medium and incubated at 
37°C in 5% carbon dioxide. Adherent biotinylated TE cells in 6WP were labeled with 200 ul 
Streptavidin-PE (Invitrogen, cat no. SA1004-1) 1:100 diluted in complete RPMI medium for 10 
minutes on ice, then washed twice in complete RPMI medium, and allowed to re-equilibrate in 
500 ul warm complete RPMI medium. B cells were isolated from PBMC from a healthy donor 
and were added in 200 ul ice-cold FCS to biotinylated TE cells at 1 million per well and 
incubated for 1 hour at 37°C in 5% carbon dioxide. B cells were retrieved by gentle 
resuspension from the adherent layer with a pipette so as to leave the majority of the adherent 
cells, and labeled with PerCP-Cy5.5-conjugated anti-human CD19, BV510-conjugated anti-
human CD20 and PE-conjugated anti-human IgM, for 20 minutes on ice, washed twice in cold 
flow buffer and subjected to flow cytometry. IgM downregulation of the B cells, and biotin label 
transfer from TE cells to B cells were measured.  
Assessment of specificity and sensitivity of GFP-antigen capture by transgenic B cells 
The sensitivity and specificity of antigen-GFP uptake as a marker of cognate antigen capture 
were assessed using B cells from transgenic IgHMOG mice, whose BCR recognizes the 
extracellular domain of myelin oligodendrocyte glycoprotein (MOG). Wild type and IgHMOG 
mouse splenocytes were quickly thawed in 10 ml pre-warmed complete RPMI medium and put 
into the incubator for one hour at 37°C, centrifuged and resuspended in ice-cold separation 
buffer, and B cells were isolated using mouse CD19 microbeads from Miltenyi (cat no. 130-052-
201). IgHMOG B cells were labeled with cell trace violet, diluted with wildtype B cells at 1:100, 
1:1000 and 1:10,000 and co-cultured for 2.5 hours with HEK cells expressing the fusion protein 
MOG-GFP. B cells were retrieved, labeled with anti-B220 and anti-CD69 antibodies and 
subjected to flow cytometry. MOG-GFP uptake by the B cells was analyzed by gating on scatter 
to select live, single cells. The population of putatively antigen-specific, i.e., CD69high and GFPhigh 
cells was then examined for CTV labeling to determine the numbers of true and false positives 
and negatives, and thus the sensitivity and specificity of the technique.  
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The specificity was calculated as: true negatives divided by the sum of true negatives plus false 
positives. The sensitivity was calculated as: true positives divided by the sum of true positives 
plus false negatives. 
Statistical analysis 
We used GraphPad PRISM 6 to graph and analyze the data for ELISA and flow cytometric 
antibody assays. To test the significance of differences in numbers of antigen-specific cells 
between GFP-capturing and non-capturing populations, a threshold was set at mean plus five 
standard deviations of the negative distribution, and the frequencies of cells above this threshold 
were compared by fisher's exact test or chi-square test as specified in the figure legends. 
 
RESULTS 
Proof of principle using BCR transgenic mouse B cells 
To investigate the detectability of different B cell frequencies by flow cytometry, we used 
transgenic mouse B cells of known specificity. We labeled B cells from transgenic mice, whose 
BCR is specific for myelin oligodendrocyte glycoprotein (MOG), with cell trace violet, mixed them 
with unlabeled polyclonal wildtype B cells at three different dilutions (1:100, 1:1000 and 
1:10,000) and cultured them for two hours with HEK MOG-GFP cells. Retrieved B cells were 
labeled with anti-mouse CD69 and anti-mouse B220 antibody and subjected to flow cytometry. 
After the co-culture a distinct population of B cells with upregulated CD69 and significant uptake 
of GFP-tagged MOG could be detected (Figure 1A, 1B). To confirm the MOG-specificity of the 
CD69high-GFPpos B cell population, we plotted GFP against CTV and could detect MOG-specific 
B cells when diluted at 1:10,000 with a specificity of 99.9% and a sensitivity of 75.8% (Figure 
1B). These promising results encouraged us to use to same approach to detect human antigen-
specific B cells of physiologically realistic frequencies.  
Establishment of HA antigen donor cell line 
We generated a TE cell line that stably expresses wildtype HA on the surface (referred to as 
“TE HA” throughout the text). To verify the HA expression we tested sera from healthy donors 
from before and after influenza vaccination for binding to HA, compared to binding to non-
expressing control cells (TE 0). Figure 2A shows staining of both cell lines using serum from 
before and after influenza vaccination from one healthy donor. Sera after vaccination showed a
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stronger binding to the TE HA cells. This indicates that the HA protein is expressed in an intact 
protein conformation.  
We next examined whether human B cells can capture HA expressed on TE cells. To 
investigate this question we prelabeled the surface of HA-expressing cells and non-expressing 
control cells with biotin, cultured human B cells with these biotinylated cells, retrieved and 
labeled them with two B cell markers (anti-human CD19 and anti-human CD20) as well as with 
anti-human IgM and looked at the IgM downregulation and the biotin label transfer from the TE 
cells to the B cells. It turned out that the majority of the B cells took up HA from the HA 
expressing cell line (Figure 2B). Due to the expected low frequency of HA-specific B cells, we 
hypothesized that the binding was rather due unspecific binding via sialic acid than due to a 
specific recognition of HA by the B cells. It is known that influenza HA contains a sialic acid 
binding site that interacts with sialic acids present on the surface of most cell types including to 
B cells. 
To reduce this sialic acid mediated, BCR-independent binding (reported in 2014, by James R. R. 
Whittle and colleagues) we generated a cell line expressing a mutated form of HA; we 
incorporated a tyrosine-to-phenylalanine point mutation at HA1 position 98 (Y98F) to the sialic 
acid binding domain. Repeating the experiments described above, using the TE cell line 
expressing the mutated HA (referred to as “TE mHA” throughout the text) showed that the 
antigen-specific binding of antibodies from human sera as well as the binding of the rabbit 
monoclonal anti-HA antibody RM10 was not compromised by this mutation (Figure 2C), but the 
antigen-independent interaction between B cells and the HA-expressing cells was eliminated 
(Figure 2D).  
Antigen-GFP capture enables significant enrichment of human antigen-specific B cells 
The approach of labeling the membrane of TE cells with biotin shows a lower specificity than 
using adherent cells expressing an antigen-GFP fusion protein, as described in the first section. 
Furthermore, the biotin approach contains in addition to the chemical biotinylation also a 
streptavidin incubation step, which influences the adherence of the TE cells.  
The technique described above developed for identifying MOG-specific mouse B cells requires a 
stably transfected cell line expressing the antigen of interest fused to GFP. Accordingly, we 
focussed on generating a cell line expressing the mutated HA fused to GFP (referred to as 
“TE mHA-GFP” throughout the text) and investigated the capture of HA-GFP by human B cells. 
B cells from a healthy donor after influenza vaccination were cultured with TE mHA-GFP cells for 
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two hours to allow antigen uptake, retrieved and labeled with anti-human CD19. ELISpot plates 
were coated with HA, anti-IgG or BSA and either polyclonal non-cultured B cells were added 
(Figure 3A) or GFP-capturing and non-capturing B cells were FACS-sorted directly into ELISpot 
plates (Figure 3B), incubated for three days and detected with anti-IgG. Spots on anti-IgG 
coated wells indicate the total number of IgG secreting B cells, whereas spots on HA-coated 
wells indicate B cells secreting HA-specific IgG. Comparing non-cultured polyclonal B cells 
(Figure 3A) and HA-GFP-capturing, HA-specific B cells from the same donor (Figure 3B), we 
see that the technique enables a significant enrichment (approximately 150-fold; 0.024% to 
3.6%) of antigen-specific cells.  
B cells isolated by antigen-GFP capture FACS include both IgG- and IgM-secreting 
antigen-specific clones  
To verify the antigen-specificity of the putatively HA-specific B cells and to enable a confident 
estimate of the quantitative enrichment we took advantage of the high-throughput activation and 
expansion of single sorted B cells using a mixture of recombinant cytokines described by Huang 
and colleagues [12]. 
FACS-sorted, GFP-capturing and non-capturing B cells were plated at approximately 1.6 cells 
per well into 384WP wells containing a cytokine mixture to induce activation and expansion of 
the B cells. Antibodies in the supernatants of these B cell cultures were screened by microELISA 
using anti-IgG or anti-IgM capture antibodies to measure total immunoglobulin, HA, tetanus 
toxoid, and BSA. Binding to each antigen was detected separately with anti-human IgG and anti-
human IgM secondary antibodies, while total immunoglobulins bound to isotype-specific capture 
antibodies were detected only with detection antibodies with the same isotype specificity as the 
capture antibody. Figure 4 shows the ODs corresponding to the three antigens and the two 
immunoglobulin isotypes of 1920 supernatants from GFP-capturing B cell cultures and 1920 
supernatants from non-capturing B cell cultures. 39.6% of the GFP-capturing B cells (761 
supernatants) and 38.9% of the non-capturing B cells (747 supernatants) produced IgG 
(Supplementary Figure 1A). Within the GFP-capturing B cells 4.5% (35 supernatants) of the IgG-
producing supernatants showed specific HA-binding activity whereas within the non-capturing 
B cells, none of the IgG-producing supernatants showed specific HA-binding activity. One 
supernatant from the non-capturing population exhibited HA-binding above our threshold of 2.5 
(Supplementary Figure 1B), but this supernatant also bound strongly to BSA and tetanus toxoid 
(Figure 4).  
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IgM reactivities to all three antigens were more broadly distributed than the IgG reactivities of the 
same supernatants, both those from GFP-capturing and non-capturing B cells. Within the 
supernatants from GFP-capturing B cell clones, no clearly separated population with a strong 
reactivity to HA is visible. Because of the high level of IgM binding to the negative control 
antigens, we hypothesized that the HA-specific signal was being masked by non-specific 
binding. To evaluate this possibility, we plotted the anti-HA reactivities against either anti-BSA 
(Figure 5A) or against anti-tetanus toxoid (Figure 5B). In these plots, HA-specific reactivity 
should appear as a high value on the HA axis compared to the control antigen. The clearly 
separated group of supernatants within the coloured triangles shows that this is the case for the 
GFP-capturing IgG-reactive B cell clone supernatants. 
IgM binding to HA in supernatants from both GFP-capturing and non-capturing B cell clones was 
frequently associated with high anti-BSA, or anti-tetanus activity, suggesting that IgM is not as 
specific as IgG. Examining only the region of the plots with high HA and low control antigen 
binding, there are a small number of supernatants that appear to contain HA-specific IgM, but 
only in the comparison with tetanus toxoid is the frequency of these supernatants statistically 
significantly greater in the GFP-capturing cell cultures than in the non-capturing cell cultures. 
Antigen-GFP capture enables immortalization and cloning of antigen-specific B cells 
The high throughput B cell activation technique we used enabled confirmation of the rate of 
enrichment and antigen specificity of HA-specific B cells, but produces only limited quantities of 
antibody, and does not yield viable B cells for further study. To enable characterization of the 
antibodies by flow cytometry, and to generate immortal B cell clones, we transformed HA-
specific B cells with EBV. We repeated the experiment by culturing human B cells with TE mHA-
GFP cells, retrieved and labeled them with anti-human CD45 and FACS-sorted them into 
Eppendorf tubes for a subsequent immortalization by EBV transformation. Antibodies in the 
supernatants of the B cell clone cultures were re-screened for antigen-specificity by ELISA 
(Figure 6A) and a cell-based flow cytometric assay (Figure 6B).  
Figure 6A shows binding of the IgG and IgM from GFP-capturing or non-capturing B cell clones 
to hemagglutinin and to BSA. If detected with anti-IgG secondary antibodies, around a quarter of 
the supernatants (12 out of 46) from GFP-capturing B cell clones showed binding to HA with an 
OD 450 of > 0.25, compared to antibodies from GFP-non-capturing B cell clones, which all 
bound to HA with an OD 450 of ≤ 0.125. The anti-IgG detected supernatants in both GFP-
capturing and non-capturing B cell clones bound to BSA with OD 450 of < 0.125. If detected with 
anti-IgM secondary antibodies, supernatants from both GFP-capturing and non-capturing B cell 
Part I Results I 
30 
clones showed binding to HA which correlated with the binding to BSA, suggesting that IgM is 
not as specific as IgG. Only one supernatant in the GFP-capturing group showed high anti-HA 
IgM activity in the absence of BSA binding.  
The same supernatants were also tested for binding to mHA expressed on TE cells in a flow 
cytometric assay (Figure 6B), detecting with anti-human IgG and anti-human IgM secondary 
antibodies. If detected with anti-IgG, around a quarter of the supernatants (13 out of 46) from 
GFP-capturing B cell clones showed binding to mHA expressed on TE cells. Supernatants from 
GFP-non-capturing B cell clones did not show binding to mHA. Compared to the results from 
ELISA, IgM binding was more clearly different between supernatants from GFP-capturing and 
non-capturing B cell clones. 5 out of 46 supernatants from GFP-capturing B cell clones bound to 
mHA whereas all supernatants from GFP-non-capturing B cell clones did not show any binding 
to mHA expressed on TE cells.  
Generation of recombinant monoclonal antibodies  
Thirty-five GFP-capturing B cell cultures producing anti-HA antibodies (data points marked red in 
Figure 4) were used for cloning and the generation of recombinant monoclonal antibodies. From 
those 35 B cell cultures, which initially contained 1.6 cells per well on average, 45 different 
heavy chains and 59 different light chains were cloned. Seventy-two combinations of heavy and 
light chains were expressed recombinantly, reproducing the combinations found in the wells, 
and the secreted antibodies tested by IgG ELISA for binding to HA, tetanus toxoid, anti-IgG and 
BSA. Of those 72 combinations, 42 showed binding to HA with OD 450 > 1.7 and 5 showed 
polyspecific binding with OD 450 > 1.7 to either BSA or tetanus or both, in addition to HA. The 
remaining 25 combinations showed weak binding to HA with OD 450 < 1.7, presumably 
representing HA-nonspecific antibodies originating from B cells that were co-cultured with 
specific B cells, or non-binding combinations of heavy and light chains from specific and non-
specific donor B cells. The cloning results showed that the binding of the recombinant antibodies 
to the antigen are determined by both the heavy and light chains, although some particular 
heavy chains can mediate specific binding regardless of the light chain partner (Supplementary 
Figure 2). Supplementary Table 1 shows 27 pairs (one derived from each of 27 original GFP-
capturing B cell cultures) of immunoglobulin heavy and light chain sequences that when 
expressed as recombinant antibodies showed binding to HA by ELISA. 
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DISCUSSION 
In this study, we developed a novel method to isolate intact, living B cells that recognize 
membrane-bound, complex antigens in their native conformation. To develop this method we 
needed a model in which the target antigen is known and B cells specific for that antigen are 
present in normal human donors. Influenza hemagglutinin was chosen as an appropriate model 
since healthy individuals are commonly immunized against influenza which is thought to 
increase the number of HA specific B cells [13]. In addition, influenza hemagglutinin protein 
antigens are well studied.  
To our knowledge, only little research has been done on isolating human influenza-specific 
B cells. One study, which reports on the establishment of a flow cytometric based method to 
enumerate and characterize influenza virus hemagglutinin-specific B cells was performed in a 
mouse model and focused on comparing the use of purified HA with the use of whole influenza 
virus to stain virus-specific B cells [14]. 
Our method is based on culturing human B cells with fluorescently labeled hemagglutinin-
expressing cells, followed by a FACS-sort to isolate hemagglutinin-specific B cells from other 
B cells. With this method we were able to enrich hemagglutinin-specific B cells approximately 
150-fold. We could show that B cells could be EBV-transformed or in vitro expanded after FACS-
sorting. This enables testing of the specificity of the sorted B cells on a single cell level. Two 
different assays investigating the binding of antibodies to hemagglutinin were compared: ELISA 
and a cell-based flow cytometric assay. In the cell-based flow cytometric assay we investigated 
whether antibodies bind to membrane-bound hemagglutinin expressed in the native 
conformation on adherent cells, while ELISA uses recombinant protein antigen bound to plastic 
whose conformation is unknown. Previous studies have suggested that antibody binding differs 
depending on the antigen conformation, and therefore that results from the two kinds of assay 
are not interchangeable [15-17]. In 1999, a study by Brehm and colleagues described ten 
different demyelinating monoclonal antibodies which recognize the extracellular immunoglobulin-
like domain of human myelin oligodendrocyte glycoprotein (hMOG) expressed on transfected 
fibroblasts but failed to recognize MOG peptides when assessed by ELISA [18]. A study by 
Pröbstel and colleagues reported on the importance of using a cell-based assay instead of 
ELISA to distinguish anti-MOG immunoglobulin positive patients from controls [19]. In our study 
we also observed different binding results for individual antibodies depending on the assay 
paradigm. Not all supernatants from FACS-sorted, EBV-transformed B cell cultures that bound 
Part I Results I 
32 
to hemagglutinin expressed on adherent cells, showed binding to hemagglutinin in ELISA. In 
contrast, only one single supernatant was positive by ELISA and failed to show a significant 
binding to hemagglutinin expressed on adherent cells.  
In the last thirty years, different techniques have been established to isolate antigen-specific 
B cells that recognize conformational epitopes, most of them using antigens in their soluble 
form. However, in some cases it is impossible to mimic a real native conformation using soluble 
antigens as shown by autoimmune antibodies in myasthenia gravis that bind to acetylcholine-
receptors consisting of membrane-protein clusters [7]. At present, no technique exists to isolate 
B cells that recognize such membrane-bound, complex antigens. We believe that our study fills 
exactly this gap; the technique enables the isolation of antigen-specific B cells which recognize 
and capture membrane-bound protein antigens. A comparison of the results from ELISA, which 
uses soluble protein antigen of unknown conformation, with the results from the cell-based flow 
cytometric assay, shows that our cell-based technique catches more of the relevant B cells 
compared to methods using soluble antigens to isolate antigen-specific B cells.  
A limitation of our study is that the antigen has to be known or at least assumed in order to label 
it fluorescently. To overcome this issue, it would be necessary to label the whole surface of the 
antigen-expressing cells chemically with e.g. biotin and looking at the antigen-uptake of the 
B cells by analyzing the biotin-transfer from the adherent cells to the B cells, comparing B cells 
cultured in antigen-expressing and non-expressing cells. Another limiting factor of our method is 
the EBV transformation rate which is relatively low, as reported in previous studies [20,21]. If 
only a small percentage of the FACS-sorted B cells get transformed, the chance is high to lose 
relevant B cells. In our study we were interested in the whole B cell population, and therefore 
labeled the B cells with one marker to be able to differentiate between B cells and adherent 
TE cells. For a more specific sorting of the B cell population of interest, activation markers like 
CD69 could be included. CD69 upregulation is one of the earliest and most sensitive measures 
of antigen recognition [22], and was associated with antigen capture in our experiments with 
mouse cells. In addition, markers for various B cell subpopulations could be added, in order to 
specifically detect memory cells, plasma cells, particular immunoglobulin isotypes, or other B cell 
subsets.  
The precise identification of epitopes, especially in the field of autoimmune diseases, can be a 
step towards new treatment approaches, like antigen-specific depletions of relevant B cells. 
A proof of concept for such a therapy has been shown in 2012 by Henry and colleagues in an 
animal model of diabetes [23]. Other benefits gained from isolated antigen-specific B cells are
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the possibility of tracking a vaccine success or to generate possible therapeutic antibodies by 
cloning the B cell receptor and generating recombinant antibodies. Current studies on the 
human immunodeficiency virus for example, are investigating in animal models the influence of 
injections of broadly neutralizing antibodies on the prevention and treatment of the disease [24].  
We believe that our technique, using the approach of culturing human B cells with cells 
expressing the antigen of interest fused to GFP, will enable us to identify B cells whose antigens 
are known. For unknown antigens, which are found on a particular cell type, the approach of 
culturing human B cells with biotinylated antigen-expressing cells could be applied. A possible 
application of this technique would be to identify and clone human anti-tumor antibodies from 
patients.  
 
ACKNOWLEDGMENTS 
We thank the staff of the flow cytometry core facilities of the DBM for technical help. Funding 
was from the Swiss National Science Foundation (grant number 310030_149966). 
 
REFERENCES 
1. Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody 
therapeutics: history and future. Curr Opin Pharmacol 2012;12:615–22.  
2. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013;341:1192–8.  
3. Forsström B, Axnäs BB, Rockberg J, Danielsson H, Bohlin A, Uhlen M. Dissecting 
antibodies with regards to linear and conformational epitopes. PLoS ONE 
2015;10:e0121673.  
4. Oshiba A, Renz H, Yata J, Gelfand EW. Isolation and characterization of human antigen-
specific B lymphocytes. Clin. Immunol. Immunopathol. 1994;72:342–9.  
5. Irsch J, Hunzelmann N, Tesch H, Merk H, Maggi E, Ruffilli A, et al. Isolation and 
characterization of allergen-binding cells from normal and allergic donors. 
Immunotechnology 1995;1:115–25.  
 
Part I Results I 
34 
6. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, et al. 
Isolation of Human Monoclonal Antibodies That Potently Neutralize Human 
Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A 
Complex. Journal of Virology 2010;84:1005–13.  
7. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, et al. IgG1 antibodies to 
acetylcholine receptors in “seronegative” myasthenia gravis. Brain 2008;131:1940–52.  
8. Fleire SJ. B Cell Ligand Discrimination Through a Spreading and Contraction Response. 
Science 2006;312:738–41.  
9. Natkanski E, Lee WY, Mistry B, Casal A, Molloy JE, Tolar P. B Cells Use Mechanical 
Energy to Discriminate Antigen Affinities. Science 2013;340:1587–90.  
10. Beadling C, Slifka MK. Quantifying viable virus-specific T cells without a priori knowledge 
of fine epitope specificity. Nat Med 2006;12:1208–12.  
11. Whittle JRR, Wheatley AK, Wu L, Lingwood D, Kanekiyo M, Ma SS, et al. Flow Cytometry 
Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from 
Multiple Ig Heavy-Chain Lineages. Journal of Virology 2014;88:4047–57.  
12. Huang J, Doria-Rose NA, Longo NS, Laub L, Lin C-L, Turk E, et al. Isolation of human 
monoclonal antibodies from peripheral blood B cells. Nature Protocols 2013;8:1907–15.  
13. Jahnmatz M, Kesa G, Netterlid E, Buisman A-M, Thorstensson R, Ahlborg N. 
Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-
cell responses. Journal of Immunological Methods 2013;391:50–9.  
14. Doucett VP, Gerhard W, Owler K, Curry D, Brown L, Baumgarth N. Enumeration and 
characterization of virus-specific B cells by multicolor flow cytometry. Journal of 
Immunological Methods 2005;303:40–52.  
15. Xu Y, Zhang Y, Liu C-Y, Peng B, Wang J-M, Zhang X-J, et al. Serum antibodies to 25 
myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis 
optica: clinical value for diagnosis and disease activity. Chin Med J (Engl) 
2012;125:3207–10.  
Part I Results I 
35 
16. Haase CG, Guggenmos J, Brehm U, Andersson M, Olsson T, Reindl M, et al. The fine 
specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients 
with multiple sclerosis and normal healthy controls. Journal of Neuroimmunology 
2001;114:220–5.  
17. Khalil M, Reindl M, Lutterotti A, Kuenz B, Ehling R, Gneiss C, et al. Epitope specificity of 
serum antibodies directed against the extracellular domain of myelin oligodendrocyte 
glycoprotein: Influence of relapses and immunomodulatory treatments. Journal of 
Neuroimmunology 2006;174:147–56.  
18. Brehm U, Piddlesden SJ, Gardinier MV, Linington C. Epitope specificity of demyelinating 
monoclonal autoantibodies directed against the human myelin oligodendrocyte 
glycoprotein (MOG). Journal of Neuroimmunology 1999;97:9–15.  
19. Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to 
MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 
2011;77:580–8.  
20. Hui-Yuen J, McAllister S, Koganti S, Hill E. Establishment of Epstein-Barr virus growth-
transformed lymphoblastoid cell lines. J Vis Exp 2011; 
21. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nature 
Reviews Immunology 2003;3:801–12.  
22. Fazekas de St Groth B, Smith AL, Higgins CA. T cell activation: in vivo veritas. Immunol. 
Cell Biol. 2004;82:260–8.  
23. Henry RA, Kendall PL, Thomas JW. Autoantigen-specific B-cell depletion overcomes 
failed immune tolerance in type 1 diabetes. Diabetes 2012;61:2037–44.  
24. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, et al. A single 
injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 
2016;533:105–9.  
 
 
 
Part I Results I 
36 
FIGURE LEGENDS 
Figure 1. Assay to investigate the detectability of different B cell frequencies by flow cytometry 
using transgenic mouse B cells. CTV-prelabeled MOG-specific B cells were diluted with wildtype 
B cells, co-cultured with HEK MOG-GFP cells, labeled with anti-B220 and CD69 antibody and 
subjected to flow cytometry. (A) Shows the gating strategy. The right-hand side dot plot contains 
a purple square indicating the putatively MOG-specific B cells. (B) In all three frequencies 
(1:100, 1:1000 and 1:10,000) GFP-positive and CD69-high cells could be detected (three top 
plots), as indicated as purple squares showing the percentage of double-positive cells. Those 
cells were confirmed as MOG-specific B cells by looking at their CTV-signal (three bottom plots). 
The specificities and sensitivities of this assay are shown underneath.  
Figure 2. (A) Binding of human serum antibodies to wildtype hemagglutinin (HA) expressed on 
adherent TE cells (TE HA). Histogram showing IgG anti-HA binding activity from serum from 
before and after influenza vaccination to HA-expressing (orange and green lines) and non-
expressing cells (TE 0, red and blue lines). (B) Binding of human B cells to wildtype HA 
expressed on adherent TE cells by looking at the biotin label transfer from TE cells to B cells. 
Both TE HA and TE 0 cells were prelabeled with biotin before adding human B cells for co-
culture. Red line shows B cells co-cultured with TE 0, blue line shows B cells co-cultured with 
wildtype HA-expressing cells. (C) HA-expression of mutated cell line (green line) measured by 
flow cytometry using rabbit monoclonal anti-HA antibody RM10 (left histogram) and human 
serum after influenza vaccination (right histogram) compared to non-expressing cells (TE 0, blue 
line). (D) Binding of human B cells to Y98F-mutant HA expressed on adherent TE cells (TE 
mHA) by looking at the biotin label transfer from TE cells to B cells. Both TE mHA and TE 0 cells 
were prelabeled with biotin before adding human B cells for co-culture. Red line shows B cells 
co-cultured with TE 0, green line shows B cells co-cultured with mutated HA-expressing cells. 
Figure 3. Confirmation of antigen specificity by human IgG B cell ELISpot. Wells were coated 
with HA, anti-IgG or BSA and detected with anti-IgG. Numbers in blue italics represent the 
number of counted spots. The black numbers below represent the overall spot area in mm2. (A) 
B cells from a healthy donor two weeks after influenza vaccination were added to the plate at 
100,000 or 10,000 cells per well and incubated for three days at 37°C. (B) B cells were co-
cultured with HA-GFP expressing cells for two hours, retrieved, labeled with anti-human CD19 
and sorted by FACS. Increasing numbers (100-400, shown on the left of the figure) of
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GFP-capturing and GFP-non-capturing B cells were sorted directly into ELISpot plate and 
incubated for three days at 37°C. 
Figure 4. High-throughput B cell activation and supernatant screening by microELISA. B cells 
from a healthy donor two months after influenza vaccination were co-cultured with HA-GFP-
expressing cells for three hours, retrieved and labeled with anti-human CD45. GFP-capturing 
and non-capturing B cells were sorted and plated at approximately 1.6 cells per well into 384WP 
containing a cytokine mixture to induce activation and expansion. Supernatants from those 
B cell clones were measured by ELISA for their binding capacity to three different antigens (HA, 
tetanus toxoid and BSA) and two controls (anti-IgG or anti-IgM), looking at IgG and IgM 
specificity. The horizontal axes show the three different coating antigens including the two 
controls and the vertical axes show the OD 450. Anti-HA IgG-specific supernatants above the 
OD 450 of 2 are marked in red. The upper graph shows supernatants from both GFP-capturing 
and non-capturing B cell clones detected with anti-IgG and the lower graph shows the same 
supernatants detected with anti-IgM.  
Figure 5. High-throughput B cell activation and supernatant screening by microELISA. Biaxial 
plots comparing (A) HA binding against BSA or (B) HA binding against tetanus toxoid, for the 
same supernatants as shown in figure 4. The blue shaded triangles represent the regions where 
the difference (OD 450 HA minus OD 450 BSA) is greater than or equal to the mean plus five 
SD of this difference for the whole population. The pink shaded triangles represent the regions 
where the difference (OD 450 HA minus OD 450 tetanus toxoid) is greater than or equal to the 
mean plus five SD of this difference for the whole population. P value is calculated by chi-square 
test comparing proportions of HA binding supernatants between GFP-capturers and non-
capturers. 
Figure 6. Assessment of antigen-specificity of putatively HA-specific sorted B cells. (A) Sorted 
GFP-capturing and non-capturing B cells were immortalized with Epstein-Barr virus (EBV) and 
cultured for two weeks at 37°C. The immunoglobulin concentrations in the supernatants were 
measured by ELISA for IgG (top plots) and IgM (bottom plots) specificity. Wells were coated with 
HA or BSA. Anti-HA and anti-BSA OD 450 were plotted against each other. Vertical broken line 
shows the cutoff of mean plus five SD (of the HA OD 450 from the GFP-negative population). 
P value is calculated by fisher’s exact test comparing proportions of HA binding supernatants 
between GFP-capturers and non-capturers. Points colored red are explained below. (B) The 
same supernatants were measured by a cell-based flow cytometry assay, comparing 
immunoglobulin binding to mutated HA-expressing (TE mHA) and non-expressing cells (TE 0). 
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Vertical axis shows the ratio of geometric mean immunofluorescence of TE mHA divided by TE 
0. Red squares represent supernatants with a geometric mean immunofluorescence-ratio above 
the cutoff of mean plus five SD (calculated from GFP-negative population) and points 
representing these supernatants are also colored red in the dot plots above. 
 
SUPPLEMENTARY FIGURE AND TABLE LEGENDS 
Supplementary Figure 1. Frequency distribution histograms of ELISA ODs to visualize the 
distribution of binding and non-binding supernatants. The horizontal axis shows the OD 450 and 
the vertical axis the number of B cell culture wells. (A) Frequency distribution of IgG capture 
ELISA ODs among supernatants from GFP-capturing and non-capturing B cells to enable 
determination of the cut-offs above which supernatants were considered IgG-positive. Cut-offs of 
1.7 for the GFP-capturing B cells and 1.2 for the non-capturing B cells were chosen (dashed 
lines). (B) Frequency distribution of HA IgG ELISA ODs among supernatants from GFP-
capturing and non-capturing B cells to enable determination of the cut-offs above which 
supernatants were considered anti-HA IgG-positive. A cutoff of 2.5 for the GFP-capturing was 
chosen, and the same cutoff was used for the non-capturing B cells (dashed lines). 
Supplementary Figure 2. HA binding propensity of recombinant monoclonal antibodies cloned 
from GFP-capturing B cell cultures (data points marked red in Figure 4). Different combinations 
of heavy and light chains were recombinantly expressed and tested by ELISA for their binding 
capacity to HA. The horizontal axes show the different heavy chains and the vertical axes show 
the HA OD 450. Binding OD for each combination is plotted on the vertical axis with a circle or 
square. (A) Five examples of heavy/light chain combinations originating from B cell culture wells 
containing only one single heavy chain (horizontal axis) and 2, 3 or 4 light chains. (B) Example 
of heavy/light chain combinations originating from one B cell culture well containing two heavy 
chains and three light chains (same light chains are indicated by color). (C) Example of 
heavy/light chain combinations originating from one B cell culture well containing two heavy 
chains and eight light chains (same light chains are indicated by color).  
Supplementary Table 1. Sequences of 27 pairs (one derived from each of 27 original GFP-
capturing B cell cultures) of immunoglobulin heavy and light chain sequences that when 
expressed as recombinant antibodies showed binding to HA by ELISA. 
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ABSTRACT  
Antibody secretion by B cells is dependent on antigen capture, followed by presentation of 
antigenic peptides on major histocompatibility class II molecules to CD4 T cells. Although 
studied mostly with soluble antigens, B cells also capture antigen from the membranes of other 
cells. Using influenza hemagglutinin as a model viral antigen, myelin oligodendrocyte 
glycoprotein as a model self antigen, and transgenic B cells and T cells specific for each, we find 
that cognate antigen is rapidly captured from membranes and induces strong activation of the 
capturing B cell. Smaller quantities of other co-expressed, "bystander" antigens are co-captured 
at the same time and can be presented to T cells as well. This has implications for autoimmunity: 
viral antigen-specific B cells can activate self-reactive T cells, and conversely, self-antigen-
specific B cells can receive T cell help from virus-specific T cells, leading to the production of 
autoantibodies. These findings offer a possible explanation for the link between autoimmunity 
and viral infections.  
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INTRODUCTION 
A successful vertebrate immune system must discriminate between self and non-self antigens. 
Important checkpoints for elimination of self-reactive lymphocytes include the destruction of self-
reactive T cells in the thymus (Klein et al., 2014), and suppression of development of self-
reactive B cells in the bone marrow (Wardemann et al., 2003). Although AIRE ensures the 
expression of otherwise tissue-specific antigens in the thymus (Klein et al., 2014), the set of 
antigens expressed in the bone marrow is narrower, meaning that B cells whose 
immunoglobulin antigen receptors (B cell receptor, BCR) recognize self antigens restricted to 
other tissues can escape this selection. Normally this does not lead to autoimmunity, because 
active production of antibodies requires T cell help - peripheral B cells that encounter their 
cognate antigen cannot develop into antibody-secreting cells without positive signals from helper 
T cells. This takes place in secondary lymphoid organs, and involves extensive physical contact 
with a helper T cell whose antigen receptor (T cell receptor, TCR) recognizes a peptide 
displayed on the B cell’s major histocompatibility (MHC) class II molecules. Efficient negative 
T cell selection in the thymus therefore safeguards against the production of autoantibodies.  
However, in some individuals, autoantibodies are made and can cause debilitating disease. For 
some diseases, such as myasthenia gravis, the causal relationship between the antibody and 
the pathology is clear (Ha and Richman, 2015). For others, such as multiple sclerosis, there is a 
prevalence of certain autoantibodies, but their pathological significance is not understood 
(Hohlfeld et al., 2016). For none of these diseases is there an obvious reason for the breakdown 
of B cell tolerance.  
Unlike antigen presenting cells of the myeloid lineage, B cells capture very little antigen by non-
specific routes such as phagocytosis (Lanzavecchia, 1987). They avidly capture cognate antigen 
from solution, but this mechanism is very selective, and therefore B cells that recognize soluble 
antigens require help from T cells with a shared antigen specificity (linked recognition). 
Alternatively, B cells can capture antigen from membranes of other cells. This process differs 
significantly from capture of soluble antigen: membrane-bound antigens are multivalent, 
increasing the binding avidity in comparison to a monovalent antigen in solution (Batista and 
Neuberger, 2001); moreover they associate with other protein and lipid components of the 
membrane. We hypothesized that if these bystander molecules were co-captured with the 
cognate antigen, processed and presented to T cells, it would circumvent the antigen-specificity 
of T cell help.  
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We tested this hypothesis using adherent cells that express the CNS-restricted membrane 
protein myelin oligodendrocyte glycoprotein (MOG) as a model self-antigen, influenza 
hemagglutinin (HA) as a model viral antigen, and transgenic mouse B and T cells specific for 
each antigen. This antigen pair was chosen because both are integral membrane proteins, with 
a plausible role in autoimmunity. MOG is implicated in autoimmune neurological disorders 
(Pröbstel et al., 2011) and animal models thereof (Molnarfi et al., 2013), notably in acute 
demyelinating encephalomyelitis (Pröbstel et al., 2011), and influenza is among the most 
important known viral triggers of this autoimmune condition (Wang et al., 2010).  
 
RESULTS AND DISCUSSION 
Capture of cognate antigen from membrane is rapid and robust 
Capture of cognate antigen from membrane has been examined in molecular detail (Carrasco 
and Batista, 2006; Natkanski et al., 2013), mostly using artificial membrane preparations. We 
examined the capture of cognate antigen from membranes of live cells by IgHMOG transgenic 
B cells, whose B cell receptor (BCR) recognizes the extracellular domain of MOG (Litzenburger 
et al., 1998). When IgHMOG B cells were exposed to adherent HEK cells that express a MOG-
green fluorescent protein (GFP) fusion, GFP capture was detected in the B cells by flow 
cytometry as soon as one minute after contact, and continued to increase for more than one 
hour (Fig. 1 A, B, C, and Supplementary Movie 1). Capture was paralleled by loss of surface 
IgM, indicating internalization of the BCR-antigen complex (Fig. 1 A, B). Immunolabeling of co-
cultures showed that captured antigen and IgM associate with LAMP1-immunoreactive 
structures in the B cell, presumably lysosomes (Fig 1 D, E). Initially these structures are seen at 
the interface of B cell and antigen-expressing HEK cell (Supplementary Movie 2), but upon 
prolonged interaction they distribute throughout the B cell (Fig. 1 D, Supplementary Movie 3), by 
which point the majority of the immunoglobulin colocalizes with antigen (Fig. 1 B, E). 
Membrane antigen capture renders B cells highly antigenic for T cells 
We exposed IgHMOG B cells for 8, 12 or 20 hours to adherent TE cells that express MOG (TE 
MOG) and examined expression of activation markers by flow cytometry. We compared 
membrane-antigen-capturing B cells with identical B cells exposed to non-antigen-expressing 
TE cells, or to soluble MOG protein, or to an IgM-crosslinking antibody. Loss of surface IgM was 
similar for B cells exposed to soluble or membrane-expressed antigen, but upregulation of the 
activation markers CD69 and CD25 was far greater on the B cells exposed to membrane 
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antigen (Fig. 2 A). Upregulation of Class II MHC and CD86 was similar for the three kinds of 
BCR stimulation (Fig. 2 A).  
We next examined the presentation of captured membrane antigens to T cells by co-culturing 
IgHMOG B cells (MHC class II allotype I-Ab) with TE MOG cells, then retrieving and co-culturing 
them with 2D2 T cells, which recognise MOG 35-55 in the context of I-Ab (Bettelli et al., 2003). 
2D2 T cells exposed to IgHMOG B cells after membrane capture proliferated more strongly than 
those co-cultured with naive B cells in the presence of a high concentration of cognate peptide 
(Fig. 2 B, C). Soluble MOG protein was no more effective than peptide (Fig. 2 C). Neither B cells 
exposed to culture supernatants from antigen-expressing cells, nor to TE cells that did not 
express antigen stimulated any proliferation. This rules out involvement of secreted soluble 
antigen, or antigen-independent properties of the TE cells (Fig. 2 C). Rather, it appears that the 
act of antigen capture renders the capturing B cell highly stimulatory for T cells.  
To test this interpretation we assessed the stimulatory properties of B cells after membrane 
capture of antigens that were irrelevant for the responding T cell, with or without additional 
peptide that matched the T cell specificity. We exposed HA-specific FluBI B cells (I-Ab) to TE 
cells stably transfected with HA (TE HA) and then retrieved and co-cultured these B cells with 
2D2 T cells, in the presence or absence of exogenous MOG 35-55 peptide (Fig. 3 D). Without 
additional peptide, FluBI B cells stimulated no proliferation of 2D2 T cells, whether or not the 
B cells had previously encountered HA. With added peptide, even antigen-naive FluBI B cells 
stimulated T cell proliferation, but much less than B cells that had been previously activated by 
membrane HA capture (Fig. 2 D). The enhanced ability of B cells after membrane capture to 
stimulate T cell proliferation may thus be due to the high level of activation of B cells and the 
concomitant increase in costimulatory ligands (Fig. 2 A).  
We also measured 2D2 T cell proliferation in response to MOG-specific B cells exposed to the 
same TE cells with or without peptide. Again, without peptide, pre-exposure to membrane-
expressed MOG rendered the B cells more stimulatory for the T cells than pulsing with peptide, 
whereas the presence of HA had no effect. Most strikingly, FluBI cells exposed to TE cells that 
express both HA and MOG stimulated the proliferation of MOG-specific T cells, without the 
addition of exogenous MOG peptide. This implies that MOG had been co-captured with HA, and 
processed and presented. The co-capture of irrelevant, "bystander" antigens from cell 
membranes by B cells has implications for possible causes of autoimmunity. For example, the 
capture and presentation of T cell antigens by B cells with an unrelated specificity offers a 
possible explanation for the widely observed phenomenon that viral infections sometimes
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appear to promote autoimmune responses (Cappalletti et al., 2015; Selin et al., 2011), either 
because viral-specific B cells activate autoantigen-specific T cells, or because autoantigen-
specific B cells obtain T cell help from viral-antigen-specific T cells.  
Co-captured, non-cognate antigen is presented and can qualify B cells for T cell help 
To visualize the capture of non-cognate, "bystander" antigen, we generated an adherent HEK 
cell line stably co-transfected with MOG-GFP and HA (HEK HA MOG-GFP). We co-cultured 
these cells with IgHMOG B cells, or with FluBI B cells. Capture of MOG-GFP by IgHMOG B cells 
followed similar kinetics with or without co-expression of HA, but MOG-GFP capture by FluBI 
B cells was dependent on HA (Fig. 3 A). This bystander co-capture was as rapid as cognate 
capture, being observable after 3 minutes of contact, but quantitatively less. Not all antigens we 
examined were co-captured. For example, when FluBI B cells were exposed to TE cells that 
express HA, MOG-GFP and mOVA-Cherry, MOG-GFP was co-captured but mOVA-cherry was 
not (Fig. 3 B).  
Immunoglobulin-bound antigens may be more efficiently presented to T cells than other 
endocytosed cargo (Lanzavecchia, 1985, 1987; Drake et al., 2006; Zhang et al, 2007). To 
address whether co-acquired membrane antigens were processed and presented on MHC class 
II, we used TE cell lines stably transfected with MOG and HA, or with HA alone. Since WSN/33 
HA-specific, class II restricted transgenic T cells were not available, we added a carboxy 
terminal fusion to the hemagglutinin including amino acids 323-339 of ovalbumin (OVA), a 
peptide recognized by OT-II T cells in the context of I-Ab. IgHMOG B cells were exposed to 
TE HA-OVA, or TE MOG HA-OVA for three hours and then retrieved and co-cultured with OT-II 
T cells for four days. T cell proliferation and activation were assessed by flow cytometry of CTV 
dilution and CD25 immunofluorescence, respectively. The results in this model were consistent 
with the degree of co-capture observed previously. After exposure to TE MOG HA-OVA, IgHMOG 
B cells stimulated robust proliferation in OT-II T cells, and this was dependent on MOG (Fig. 4 A, 
B). The increase in CD25 expression was not as great as in the cognate capture condition (Fig. 
4 A), and the percentage of proliferated T cells was also lower (Fig. 4 B). We also saw secretion 
of interferon-γ, IL-2 and IL-4 during interaction between B cells presenting a co-captured antigen 
and T cells responding to that antigen, but less than was seen in the cognate capture condition 
(Fig. 4 C). Presentation of the non-cognate antigen is dependent on co-capture, because 
mOVA, which contains the OT-II epitope but is not co-captured with HA or with MOG (Fig. 3 B) is 
also not presented to OT-II T cells by IgHMOG B cells after exposure to TE MOG mOVA (Fig. 4 
D). To be certain that this result was not due to insufficient expression of mOVA , we confirmed 
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the accessibility of extracellular, membrane-bound OVA in live TE MOG mOVA cells (Fig. 4 E). 
The preferential co-capture of certain antigen pairs suggests that interactions between the 
antigens, or localization of proteins in membrane microdomains such as lipid rafts may influence 
the likelihood of co-capture. 
To test whether co-captured antigen would qualify B cells for T cell help, we used the same 
combination of model antigens, i.e., IgHMOG B cells capturing antigen from TE cells expressing 
both MOG and HA-OVA, but extended the subsequent co-culture of IgHMOG B cells with OT-II 
T cells to seven days. To exclude the involvement of BCR-independent antigen uptake, and the 
possibility that the mere fact of capturing antigen stimulates antibody production, we included 
negative controls of IgHMOG B cells interacting with TE HA-OVA or with TE MOG HA. As a 
positive control, another TE cell line was established that stably expresses MOG fused to the 
OT-II OVA epitope (TE MOG-OVA). We exposed the IgHMOG B cells to the TE cells, retrieved 
and co-cultured them with OT-II T cells, and measured anti-MOG antibodies in the culture 
supernatants. Omitting either the T cells, the OVA epitope, or MOG, no antibodies were 
detected. When OT-II T cells were present and the OVA epitope was included in the B cell 
cognate antigen, antibody production was robust. We clearly detected antibodies also when the 
OVA epitope was present on the HA antigen (Fig. 4 F). Autoreactive B cells that present co-
captured viral antigen can thus be triggered to produce autoantibodies by unrelated anti-viral 
T cells. 
B cell capture from membranes has been studied mostly in the context of antigen display to 
B cells by follicular dendritic cells in secondary lymphoid organs (Batista and Harwood, 2009; 
Cyster, 2010). We here propose that B cells could also capture cognate antigen from the 
membranes of cells that express it. Exposure to viral proteins expressed as cell membrane 
antigens is highly likely, because numerous common viruses infect leukocytes. We note that for 
the FluBI B cells, the presence of the HA-specific BCR enables influenza to infect them (Dougan 
et al., 2013). However, exposure to self antigens that are not expressed in bone marrow (and 
therefore are likely targets of non-tolerized B cells) is less likely inside the blood/lymph 
compartments where the majority of B cells are located. Extralymphatic B cells are found in the 
peritoneal and pleural cavities (Höpken et al., 2010) and in the mucosa, notably the lamina 
propria, of the respiratory, digestive and urogenital tracts (Brandtzaeg and Johansen, 2005). 
B cells are found in synovial fluid and tissues in rheumatoid arthritis patients (Scheel et al., 
2010), as well as in lesions and cerebrospinal fluid in multiple sclerosis (Krumbholz et al., 2006). 
In vitro, bystander antigen co-capture can circumvent the normal B cell / T cell common antigen
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checkpoint, and enable autoreactive T cell activation and/or autoantibody secretion (Figure 4 G). 
Because the amount of co-captured bystander antigen is small, a physiologically relevant, co-
capture-dependent autoimmune response is likely to depend also on other predisposing 
circumstances, such as chronic or repeated infection, or an MHC haplotype that favors the 
competitive binding of bystander-derived peptides.  
 
MATERIALS AND METHODS 
Mice and primary immune cells 
C57Bl/6 mice were bred in the University of Basel Mouse Core Facility. Tg(TcraTcrb)425Cbn 
(OT-II) mice on a Rag2-/- background were a kind gift from Ed Palmer (University of Basel). 
FluBI mice (Dougan et al., 2013), were bred from founder members from the Whitehead 
Institute, Cambridge, Massachusetts. IgHMOG (Litzenburger et al., 1998, also known as Th 
B cells) and C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J ("2D2") mice (Bettelli et al., 2003) were 
bred from founder members provided by Guru Krishnamoorthy and Hartmut Wekerle (Max-
Planck-Institut für Neurobiologie, Martinsried, Germany). Primary immune cells were obtained 
from spleens by mechanical disruption followed by brief settlement under gravity to remove 
tissue fragments. B cells and CD4-positive T cells were obtained by negative selection using 
biotinylated antibodies and magnetic beads from Miltenyi (Pan B Cell Isolation Kit II, mouse 130-
104-443, and CD4-positive T Cell Isolation Kit, mouse, 130-104-454). When higher purity of 
B cells was required, for example for the T cell proliferation assays, the splenocytes were first 
pre-depleted with anti-CD43 beads (Miltenyi 130-049-801) before following the manufacturer's 
instructions for the negative selection kit. All procedures involving animals were authorized by 
the Kantonale Tierversuchskommission.   
Peptides, proteins, antibodies and vital dyes 
MOG 35-55 peptide and MOG 1-125 recombinant protein were obtained from AnaSpec 
(Fremont, California). Goat anti-mouse µ-chain-specific F(ab') fragment (cat#115-006-020) was 
from Jackson Immunoresearch (West Grove PA), and FITC-conjugated anti-mouse IgM[a] from 
BD Pharmingen. Cell Trace Violet and Cell Tracker Deep Red were from ThermoFisher. 
Plasmids and cell lines 
The open reading frame encoding rat MOG was amplified with its STOP codon from pRSV-MOG 
and cloned into the blasticidin (Gibco) resistance-conferring pcDNA6.2C-EmGFP-DEST 
(Invitrogen) by gateway cloning, following the manufacturer's instructions. An expression 
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plasmid encoding A/WSN/33 influenza hemagglutinin under hygromycin (Sigma Aldrich) 
selection was purchased from Sino Biological (Beijing, China). Fusion constructs MOG-GFP, 
MOG-OVA, HA-OVA were made by template-switching PCR and cloned by Ligation 
Independent Cloning into the PigLIC vector, which confers puromycin (Gibco) resistance. The 
mOVA construct was amplified from pODpCAGGS (Ehst et al., 2003; a kind gift from Marc 
Jenkins, University of Minnesota) and cloned into PigLIC. Cells transfected with this construct 
express ovalbumin at the cell surface, which can be detected by flow cytometry on living cells 
using a polyclonal rabbit anti-OVA antibody (Ab1225, Millipore). HEK 293 embryonic kidney cells 
and TE671 rhabdomyosarcoma cells (referred to as "TE cells" throughout the text) were 
obtained from ATCC (LGC, Wesel, Germany). Cells were transfected by exposure to 2 µg/ml of 
plasmid DNA and 5 µg/ml of polyethylenimine in RPMI medium without serum for four hours. 
Cells were cultured in complete medium (RPMI medium containing 10% fetal calf serum, 100 
units/ml of penicillin and 100 µg/ml of streptomycin, all from Gibco) at 37°C in 5% carbon 
dioxide. Cells resistant to the appropriate selective antibiotic were sorted by the Department of 
Biomedicine Flow Cytometry Core after labeling as described below. Cells were tested for 
mycoplasma infection on arrival and subsequently (LookOut Mycoplasma PCR Detection Kit, 
Sigma).  
Cell Surface Antigen Confirmation and General Flow Cytometry 
For each cell line designed to express a cell membrane antigen, we verified expression at the 
establishment of the cell line, and subsequently periodically checked the expression of the 
antigen by immunofluorescence flow cytometry (see Supplementary Table 1). Adherent cells 
were washed in Phosphate-Buffered Saline (PBS), trypsinized, resuspended in complete 
medium, washed in labeling buffer (PBS, 2% FCS, 0.1% sodium azide), incubated for thirty 
minutes on ice in primary antibody, washed again, incubated with fluorescent secondary 
antibodies, washed and measured on a BD LSRFortessa flow cytometer (BD Biosciences). Cells 
known to be positive and negative for the target antigen were labeled and measured in parallel 
each time. A typical result from such an experiment is shown in Figure 4 E. When flow cytometry 
results are shown as contour plots, the contour lines are spaced at 10%. Gating strategies for 
each figure are shown in Supplementary Figure 1.  
B cell Flow Cytometry 
IgHMOG B cells isolated by negative selection were co-cultured with TE MOG or TE 0 cells for 8 - 
20 hours in complete medium at 37°C in 5% carbon dioxide, then retrieved and labeled with the 
following antibodies before analysis as above. APC-Cy7 anti-B220 (clone RA3-6B2),
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PerCP-Cy5.5 anti-CD69 (clone H1.2F3), PE-Cy7 anti-CD86 (clone GL1), APC anti-I-A/I-E (clone 
M5/114.15.2, Biolegend), PE anti-CD25 (clone PC61.5), AlexaFluor488 donkey anti-mouse IgM 
(Jackson Immuoresearch), FITC R35-95 rat IgG2a kappa isotype control. All antibodies from BD 
Biosciences unless otherwise specified.  
T cell proliferation assays 
B cells were exposed to antigen-expressing adherent cells in 25 cm2 flasks for three hours, and 
then retrieved, counted and put into 96-well plates at 50,000 per well in complete medium 
supplemented with 50 µM 2-mercaptoethanol. T cells were labeled with 5 µM Cell Trace Violet in 
Hanks' Balanced Salt Solution (Gibco) at 37°C for 15 minutes, then washed thrice in complete 
medium, counted and added to the B cell wells at 25,000 per well. After four or five days, the co-
cultures were retrieved, labeled with anti-CD19, anti-B220, anti-CD4 and anti-CD25 (all from BD 
Biosciences) and analyzed by flow cytometry on a BD LSRFortessa.  
Fixed and live cell microscopy 
For high resolution immunolabeling, B cells were added to HEK MOG-GFP cells growing in 
chambered coverslips (Ibidi, Martinsried, Germany) at 37°C and at various time points were 
fixed in ice cold 4% phosphate-buffered paraformaldehyde for 20 minutes, then washed in 
Phosphate-Buffered Saline (PBS), blocked in PBS containing 5% normal goat serum and 0.02% 
TritonX and and immunolabeled with rat anti-mouse LAMP1 (Southern Biotech), followed by 
Alexa647 conjugated goat anti-mouse IgM and Rhodamine-RedX-conjugated goat anti-rat 
antibodies, both from Jackson Immunoresearch. Images were aquired images with a Nikon a1r 
maintained by the microscopy core facility of the Department of Biomedicine, in line-scanning 
mode with a 60X 1.40 N.A. oil immersion objective, using voxel dimensions set at approximately 
Nyquist sampling. Acquisition was controlled by Nikon Elements software, and the same 
software was used to create 3-dimensional reconstructions and maximum intensity projections 
from the stacks of X-Y planes. Regions of interest were subsequently cropped, and when 
necessary to enhance visibility brightness and contrast were increased using the Fiji distribution 
of ImageJ (Schindelin et al., 2012). For Live cell imaging, a similar setup was used, but the 
B cells were prelabeled with Cell Tracker Deep Red (Invitrogen) following the manufacturer's 
instructions, and without fixing the cells, the chambered coverslips with the cells growing in 
complete medium were placed into a humidified chamber on the microscope stage, held at 37°C 
and 5% carbon dioxide by an INU-TIZ-F1 controller (Tokai Hit, Fujinomiya, Japan). The pinhole 
was opened to 5.0 Airy units, and other parameters (PMT voltages, voxel dimensions, etc.) 
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optimized to minimize laser light exposure. Approximately one frame per minute was captured, 
and frames were assembled into movies with Nikon Elements software. 
Anti-MOG antibody assay 
Anti-MOG antibodies were measured in culture supernatants by flow cytometry as previously 
described (Pröbstel et al., 2011). Supernatants were mixed with two volumes of reporter cell 
suspension in PBS / 2%FCS / 0.1% sodium azide on ice. The reporter cells include equal 
numbers of unlabeled TE MOG cells and CTV-labeled TE 0 cells. After 30 minutes on ice, the 
cells are washed, and antibodies adhering to the TE MOG cells are detected with Alexa 647 
anti-mouse IgG secondary antibodies (Jackson Immunoresearch) and measured by flow 
cytometry. TE 0 and TE MOG populations are then separated by CTV label and the ratio of 
fluorescence intensities between TE MOG and TE 0 indicates the abundance of antibody in the 
supernatant. 
Cytokine assays 
IFN-γ, IL-2, and IL-4 were quantified in supernatants from B/T cell cocultures by the MSD V-
PLEX Proinflammatory Panel 1 (mouse) electrochemiluminescent (ECL) assay (MSD: Meso 
Scale Discovery, Gaithersburg, MD) according to the manufacturer’s guidelines. Samples were 
analyzed in duplicate and the plates were read in a SECTOR Imager instrument (Meso Scale 
Discovery). 
Statistics 
Geometric mean fluorescence intensities of activation markers on B cells were analyzed by two-
way analysis of variance (time versus condition) and since an effect of condition but not of time 
was found, the effect of condition was examined by one-way analysis of variance followed by 
Dunnet's Multiple Comparison Test to compare each of the conditions against "no stimulation". 
T cell proliferation data (proportions of cells in the CTV-low gate) were analysed by one-way 
analysis of variance followed by Dunnett's test. Cytokine concentrations were log-transformed to 
improve normality and subjected to two-way anlysis of variance followed by Bonferroni-corrected 
post-hoc multiple comparisons. Anti-MOG antibody levels, expressed as ratios of geometric 
mean immunofluorescence TE MOG: TE 0 were analyzed by two-way analysis of variance 
(presence of T cells versus antigen condition), revealing a strong interaction, with an effect of 
condition limited to the T cells present condition. The Kruskal-Wallis test was therefore used to 
assess the effect of antigen condition, and Dunn's Multiple Comparison Test used to compare 
each of the conditions with the T cells absent condition.  
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FIGURE LEGENDS 
Figure 1. Capture of cognate antigen from membrane. (A) Flow cytometry of MOG-GFP 
acquisition and cell-surface IgM loss by MOG-specific IgHMOG or wild-type B cells. B cells were 
co-cultured with MOG-GFP-expressing HEK cells for the times shown, then retrieved, labeled 
with fluorescent anti-CD45R (B220), anti-IgM antibodies, washed and measured. Data shown 
are gated on scatter and B220 immunofluorescence from one of two similar experiments.  
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Tick marks on axes of bottom left plot show log 10 decades and are the same for all plots. 
Contour line intervals are 10% of the population, for which the gating strategy is shown in 
Supplementary Figure 1. (B) Graphical representation of the GFP fluorescence (solid green line) 
and IgM immunofluorescence (broken purple line) intensities shown in A. Geometric mean 
fluorescence is shown on a linear scale against time. (C) Single frames from a live cell imaging 
experiment showing the capture of MOG-GFP (green) from stably transfected HEK cells by 
IgHMOG B cells labeled with Cell Tracker Deep Red (magenta). When the top left frame was 
captured, one B cell (broken cyan arrow) was in contact with the HEK cell. Three minutes later 
(top right frame) a second B cell had made contact (cyan arrow), but has not yet obviously 
captured antigen. In the subsequent frames at 15 and 45 minutes, the accumulations of antigen 
(cyan arrows in lower frames) are visibly increasing. The entire time sequence is provided as 
Supplementary Movie 1. (D) 3D reconstructions of confocal z stacks of B cell - HEK MOG-GFP 
interactions. B cells were fixed after 3 or 60 minutes of co-culture with HEK MOG-GFP cells and 
immunolabeled for LAMP1 (red) and IgM (magenta) before confocal microscopy. Stacks of XY 
planes stacks were processed digitally to generate 3D reconstructions, and rotated to show the 
view “from the side”. The broken white arrows on each image show the level at which the planes 
shown in E were captured. Bar = 2 µm. 3D reconstructions provided as Supplementary Movies 2 
and 3. (E) "Horizontal" (i.e., parallel with the coverglass) sections through the same two cells 
shown in D. These images are maximum intensity projections of three XY-planes each, centered 
vertically at approximately the level shown by the broken white arrows in the left image of panel 
D. Bar = 2 µm.  
Figure 2. Immunological sequelae of membrane antigen capture. (A) Changes in surface 
expression of various molecules following antigen capture. IgHMOG B cells were exposed to 
TE MOG cells, or to various comparison treatments for 8 to 20 hours, then retrieved, 
immunolabeled and measured by flow cytometry. Responses of IgHMOG B cells exposed to 
different conditions are plotted in different colors, as shown in the legend. The vertical axis is the 
geometric mean fluorescence value for the population of cells in the B cell gate. Median values 
from three independent replicate experiments are shown. (*p<0.05, **p<0.01, ***p<0.001). (B) 
T cell proliferation in response to B cells presenting antigen from different sources. IgHMOG 
B cells were either exposed to TE MOG cells for 3 hours and then retrieved and co-cultured with 
MOG-specific 2D2 T cells (orange line), or else were added naive to the T cells in 96-well plates 
with 30 µg/ml of MOG 35-55 (cyan line) or without any antigen (red line). The T cells were pre-
labeled with Cell Trace Violet (CTV) to enable tracking of proliferation, and after 4 days at 37°C, 
the co-cultured cells were retrieved, labeled for B220 and TCR alpha 3.2 (expressed on 2D2 
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T cells) and subjected to flow cytometry. The range labeled “CTV low” was used to calculate the 
values used for Panel C. (C) T cell proliferation induced by B cells capturing membrane antigen, 
soluble protein, or soluble peptide. IgHMOG B cells were exposed to adherent cells and then 
retrieved for co-culture with MOG-specific 2D2 T cells, or else were co-cultured with T cells in 
the presence of the indicated antigen concentrations. 2D2 cells were pre-labeled with CTV to 
track proliferation, and after 4 days at 37°C, the co-cultured cells were retrieved, labeled and 
measured as in Panel B. The proportion of cells in the CTV-low gate is shown as a percentage 
of the total number of CD4-positive, B220-negative cells. Red bars show results from conditions 
in which B cells were pre-cultured with adherent cells, green bars from cells cultured with MOG 
35-55 peptide, and blue from cells cultured with MOG 1-125 recombinant protein. In the negative 
control no antigen was added. Other controls include exposure of B cells to antigen non-
expressing TE 0 cells, or to supernatants from TE MOG cells. (D) Effect of membrane antigen 
capture on T cell-stimulating capacity of B cells. MOG-specific IgHMOG B cells, or HA-specific 
FluBI B cells were exposed to MOG or HA, expressed in TE cell membranes. After exposure, 
B cells were retrieved and pulsed (solid bars), or not (outline bars) with 10 µg/ml of MOG 35-55 
peptide and then co-cultured with CTV-labeled MOG-specific 2D2 T cells for four days. Bars 
show percentages of T cells in the CTV-low gate. Results from one of three independent 
experiments.  
Figure 3. Flow cytometry of bystander antigen capture. (A) IgHMOG B cells, FluBI B cells, or 
wild-type B cells were exposed to HEK cells expressing MOG-GFP fusion protein and HA 
(HEK HA MOG-GFP), or to cells expressing MOG-GFP alone (HEK MOG-GFP), or not exposed 
to adherent cells for the indicated times, then retrieved, and labeled for B220 and surface 
immunoglobulin for flow cytometry. Data are representative of two experiments. (B) Co-capture 
of MOG-GFP and mOVA-Cherry with HA was compared by flow cytometry of FluBI B cells 
exposed to TE cells expressing all three antigens (third contour plot). Intensity of captured MOG-
GFP (excitation 488 nm, emission 530/30 nm) is shown on horizontal axis and of captured 
mOVA-Cherry (excitation 561 nm, emission 610/20 nm) is shown on vertical axis. TE 0 and 
TE MOG-GFP without HA were used as negative controls, and TE HA-GFP as a positive control.  
Figure 4. Immunological sequelae of bystander antigen co-capture and presentation. (A) 
IgHMOG B cells or FluBI B cells were exposed to TE cells expressing either HA fused to the OT-
II epitope (TE HA-OVA), or co-expressing both HA-OVA and MOG (TE MOG HA-OVA) for 3 h, 
then retrieved and cultured with CTV-labeled OT-II T cells for 5 d. Dot plots show CTV intensity 
against CD25 immunofluorescence for CD4-positive, CD19-negative cells. MOG (blue) is 
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recognized by the IgHMOG BCR; HA (orange) is recognized by the FluBI BCR; and the OVA 
epitope (red) presented in the context of the I-Ab MHCII expressed by both B cell types is 
recognized by the OT-II TCR. The range in the upper left plot marked “CTV-low” was used to 
calculate the percentages displayed in (B). (B) Column scatter graph showing T cell proliferation 
in three independent experiments like the one shown in A. Vertical axis shows percentages of 
CD4-positive, CD19-negative cells in the CTV-low gate. Cyan and blue circles show results from 
co-cultures wtih IgHMOG B cells previously exposed to TE HA-OVA or TE MOG HA-OVA 
respectively; orange and red circles show results from co-cultures wtih FluBI B cells previously 
exposed to TE HA-OVA or TE MOG HA-OVA respectively. Results from the four conditions 
pooled from three independent experiments were analysed by one-way ANOVA followed by 
Dunnett's test. Stars indicate significant difference from the IgHMOG + TE HA-OVA condition 
(**p<0.01, ***p<0.001). (C) Cytokine concentrations in supernatants from OT-II T cell 
proliferation assays like that shown in (A) were measured by ELISA. Color scheme is the same 
as (B). Bars show mean and error bars 95% confidence intervals of data pooled from two similar 
experiments. Results for interferon-γ (IFN-γ), interleukin-2 (IL-2), and interleukin-4 (IL-4) are 
shown as indicated on the horizontal axis. Asterisks indicate significant difference from IgHMOG 
+ TE HA-OVA condition (p<0.0001) (D) IgHMOG B cells were exposed to TE cells expressing 
OVA at the cell surface (TE mOVA, empty red bars) or co-expressing both MOG and mOVA 
(TE MOG mOVA, violet bars); or a single fusion protein (TE MOG-OVA, blue bars). After three 
hours, the B cells were retrieved and co-cultured with CTV-labeled 2D2 or OT-II T cells for 4 d, 
and then the proliferation of the T cells was assessed by flow cytometry. Vertical axis shows 
percentage of T cells in the CTV low gate. One of two experiments shown. (E) Flow cytometric 
confirmation of membrane location of MOG and OVA antigens. The TE mOVA and TE MOG 
mOVA cell lines used in the experiment shown in C were immunolabeled with mouse anti-MOG 
and rabbit anti-OVA primaries, Dylight 405 anti-mouse and Alexa 488 anti-rabbit secondaries. 
The quadrants are set to 99% of the TE 0 negative control in the bottom left quadrant. Grey 
contours show TE 0 cells, red contours show TE mOVA and blue contours show TE MOG 
mOVA. (F) MOG-specific IgHMOG B cells were exposed to adherent TE cells expressing MOG 
and HA separately; HA-OVA alone; MOG and the HA-OVA fusion; or MOG-OVA fusion 
(TE MOG-OVA), then retrieved and co-cultured with (inverted red triangles) or without (open 
blue circles) OT-II T cells. After 7 d, supernatants were assayed for anti-MOG antibodies by 
labeling MOG-expressing compared to non-expressing reporter cells by flow cytometry. Vertical 
axis shows ratio of geometric mean fluorescence between MOG expressing and non-expressing 
reporter cells. Medians of replicates pooled from three independent experiments were analyzed 
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by Kruskal-Wallis Test and each condition compared with the no T cells condition (***p<0.001). 
(G) Hypothetical model of the bystander antigen co-capture and presentation phenomenon. The 
left side represents the situation in which a viral-antigen-specific B cell co-captures self antigen 
and thereafter activates an autoreactive T cell. The right side represents the converse situation 
in which an autoreactive B cell co-captures viral antigen and fraudulently gains T cell help from a 
viral-antigen-specific T cell, leading to the secretion of autoantibodies. 
 
SUPPLEMENTARY FIGURE AND MOVIE LEGENDS  
Supplementary Table 1. Properties and origins of stably transfected cell lines and their parental 
stocks. 
Supplementary Figure 1. Gating strategies for flow cytometry figures. For each labeled 
Figure panel, gating strategies are shown with the largest population at the top and successively 
reduced populations going down the page.  
Supplementary Movie 1. Live cell imaging of MOG-specific B cells capturing MOG-GFP (green) 
from stably transfected HEK cells by IgHMOG B cells labeled with Cell Tracker Deep Red 
(magenta). Frames are separated by approximately one minute. 
Supplementary Movie 2. 3D reconstruction of confocal z stack of B cell - HEK MOG-GFP 
interaction fixed at 3 minutes after contact, and immunolabeled for LAMP1 (red) and IgM 
(magenta) before laser scanning confocal microscopy. Stacks of XY planes stacks were 
processed digitally to generate 3D reconstructions, and then rotated to create successive frames 
of the movie in order to show the spatial location of the B and HEK cells and the antigen-IgM 
complexes being internalized by the B cell. 
Supplementary Movie 3. 3D reconstruction of confocal z stack of B cell - HEK MOG-GFP 
interaction fixed at 60 minutes after contact. Other than the time before fixation, exactly 
analogous to Supplementary Movie 2. 
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cell line transfected antigen source
antibody used to 
verify surface 
expression
TE 0 no added antigen ATCC CRL-8805
TE MOG  MOG, i.e., native Myelin 
Oligodendrocyte glycoprotein 
from Rattus rattus
NM_022668.2  
PMID: 10428054 
8.18C5
TE HA HA, i.e., native hemagglutinin 
from influenza A/WSN/33
ACF54598.1 FluBI mouse 
serum
HEK no added antigen ATCC CRL-1573
HEK MOG-GFP MOG aa 1-204 fused to GFP 8.18C5
HA FluBI mouse 
serum
MOG aa 1-204 fused to GFP 8.18C5
TE MOG-GFP MOG aa 1-204 fused to GFP 8.18C5
TE MOG HA MOG 8.18C5
HA FluBI mouse 
serum
TE mOVA mOVA - a fusion protein 
comprising the signal peptide 
from H-2 Kb, the full sequence of 
chicken ovalbumin (OVA), and the 
transmembrane domain of H-2 
Db, which results in extracellular 
membrane expression.
 pODpCAGGS   
PMID: 14525595 
AB1225
TE MOG mOVA MOG 8.18C5
mOVA AB1225
TE MOG-OVA MOG aa 1-204 fused to full length 
chicken ovalbumin
8.18C5
TE HA-OVA HA-OVA i.e.,   A/WSN/33 HA 
fused to amino acids 312 to 345 
of chicken ovalbumin (this 
includes the epitope recognized 
by OT-II T cells
FluBI mouse 
serum
TE MOG HA-OVA MOG 8.18C5
HA-OVA FluBI mouse 
serum
HEK HA MOG-GFP
Supplementary Table 1.
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Outlook  
In the first part of this study we developed a sensitive method for identifying antigen-specific 
B cells in humans. The long-term goal of this study is to identify autoantigen-specific B cells in 
patients and elucidate their role in the pathology of autoimmune diseases. One potential 
problem could be that the population of antigen-specific B cells may be too small to be detected 
over background. However, the technique does not need to be perfectly specific. Even an 
enrichment of 100 or 1000 fold would provide a useful starting point for the application of other 
techniques like the transformation with EBV for the generation of single B cell clones. For this 
purpose we have generated a cell line expressing GFP-tagged MOG and we will attempt to 
isolate and immortalize B cells from patients with serum antibodies against MOG. Ideally this 
technique will enable us to recombinantly express these autoreactive antibodies to test their 
pathogenicity in animal models.  
In the second part of the presented work we tested a novel hypothesis linking B cells, viral 
infection and autoimmunity. We showed that B cells capture not only cognate antigens but 
simultaneously co-capture "bystander" antigens and present both to T cells. The next step is to 
examine this question with human B cells and also in parallel in an animal system in vivo. We 
want to characterize the ability of B cells to acquire membrane-expressed antigen in different 
tissues in vivo. The future goal is to determine whether the phenomenon of bystander antigen 
co-capture can lead to T cell activation and antibody secretion in vivo as it does in vitro. 
A possible, physiologically realistic paradigm would be that B cells capture antigen in vivo, after 
induction of viral antigen expression using adeno-associated viral vector encoding both cognate 
and non-cognate antigen.  
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GNbAC1, a humanized monoclonal antibody  
against the multiple sclerosis associated retrovirus envelope protein 
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Abbreviations 
CNS  central nervous system 
 
CSF  cerebrospinal fluid 
 
EDSS  expanded disability status scale 
 
ELISpot enzyme-linked immunospot 
 
Env  envelope protein  
 
HERV  human endogenous retrovirus  
 
HERV-W human endogenous retrovirus type W family 
 
IFN-γ  interferon-gamma  
 
IgG4  immunoglobulin G4 
 
IL-1ß  interleukin-1 beta 
 
IL-6  interleukin-6 
 
LPS  lipopolysaccharide 
 
mAb  monoclonal antibody 
 
MBP  myelin basic protein 
 
MS  multiple sclerosis 
 
MSRV  multiple sclerosis associated retrovirus 
 
MSRV-Env multiple sclerosis associated retrovirus envelope protein 
 
OPCs  oligodendroglial precursor cells 
 
PBMC  peripheral blood mononuclear cells 
 
TLR4  Toll-like receptor 4 
 
TNF-α  tumor necrosis factor alpha 
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Summary 
We reported the results of immunological monitoring of patients enrolled in a randomized, 
placebo-controlled, single-blind, phase 2a study testing two doses of GNbAC1 in patients with 
multiple sclerosis (MS). GNbAC1 is a recombinant, humanised, IgG4 monoclonal antibody 
directed against the envelope protein (Env) of the multiple sclerosis associated retrovirus 
(MSRV), a human endogenous retrovirus of the HERV-W family. The hypothesis that binding of 
MSRV-Env protein to Toll-like receptor 4 (TLR4) activates monocytes predicts that blocking this 
binding with GNbAC1 should decrease monocyte activation in patients with MS. 
Ten MS Patients with a mean age of 53 years and a mean expanded disability status scale 
(EDSS) score of 4.8 were randomized into two groups (2 or 6 milligrams of GNbAC1 per 
kilogram of body weight given at 4 week intervals for 12 months). In addition to safety and 
clinical monitoring, three immunological parameters were followed: (i) T cell response to myelin 
and viral antigens by ELIspot using peripheral blood mononuclear cells (PBMC); (ii) Monocyte 
TLR4 signaling measured by flow cytometry of p38 phosphorylation; and (iii) general immune 
status as reflected in proportions of lymphocytes with given phenotypes. 
In the immunological substudy (Results I of Part II of the presented work) ten patients and yoked 
healthy volunteers were followed. T cell response, as measured by interferon-gamma (IFN-γ) 
ELISpot, to viral antigens was robust throughout the study for both healthy subjects (range 22 to 
322 spots per 200,000 PBMC) and patients (range 30 to 534 spots per 200,000 PBMC). 
Response to the myelin antigen Myelin Basic Protein (MBP) was not different from negative 
control in any subject at any time point. TLR4 signaling was analyzed before treatment start and 
at several timepoints after treatment by measuring phosphorylated p38 using intracellular 
immunofluorescence flow cytometry of CD33-positive cells, with and without lipopolysaccharide 
(LPS) stimulation. Without stimulation, fewer than 10% of monocytes showed p38 
phosphorylation in patients and in controls at all time points, other than one time-point for one 
patient, in whom elevated C-reactive protein was also detected, suggesting an inflammatory 
infection. LPS stimulation (1 nanogram per milliliter in whole blood) resulted in almost 100% 
monocyte p38 phosphorylation in both patients and controls. There was a non-significant trend 
towards a reduced monocyte activation during treatment compared to before treatment. Immune 
cell subsets (CD4+ and CD8+ T cells, monocytes, and B cells) were stable over the treatment.  
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These results suggest that GNbAC1 administration is not associated with any deficit in T cell 
response to viral antigens. TLR4 activation might be reduced by the treatment. However, this 
result did not reach statistical significance probably due to the small number of investigated 
patients. 
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Introduction 
Human endogenous retroviruses (HERV) represent approximately 8% of the human genome. 
Researchers assume that during primate evolution, a viral infection led to the integration of 
retroviral genetic material into the germline of superior primates that was subsequently passed 
on to their offspring [1,2]. The first reported observation of retrovirus-like particles with reverse 
transcriptase activity was made in leptomeningeal and macrophage cell cultures from patients 
with multiple sclerosis (MS), suggesting a viral origin of this disease [3]. Further molecular 
characterization of this multiple sclerosis associated retrovirus (MSRV) revealed that it was not a 
classical infectious exogenous retrovirus but expressed by genes from the human endogenous 
retrovirus type W family (HERV-W) [4]. Most of the contemporary HERV copies are inactivated 
by mutations, deletions, or silenced by epigenetic modifications, and therefore unable to encode 
functional proteins [5,6]. However, several chromosomal HERV copies have retained potential 
open reading frames possibly derived from viral genes [7-9]. Exogenous viral agents, such as 
Herpesviridae, appear to be able to trigger the reactivation of MSRV transcription and therefore 
might be associated with the epidemiology of MS without showing a causative role in the 
disease [10,11]. These observations suggest that the reactivation of silent MSRV might be a 
possible link between environment and the onset of MS [12]. 
Following the initial report of isolation of MSRV envelope protein (MSRV-Env) from cerebral 
tissues of MS patients, various studies have proposed links between the expression of MSRV-
Env and MS. It has been reported that the presence of MSRV in cerebrospinal fluid (CSF) 
correlates with clinical progression and prognosis of MS [13]. In addition, immunohistochemical 
analyses of post-mortem brain tissue from MS patients have shown that the MSRV-Env is 
expressed in MS plaques and its level of expression correlates with the plaque activity [14,15]. 
The MSRV-Env consists of 3 domains: the signal peptide, the transmembrane domain and the 
surface domain, which has been reported to be an agonist of the Toll-like receptor 4 (TLR4) [16]. 
Through this activation of the TLR4 pathway, it is proposed that MSRV-Env induces the release 
of pro-inflammatory cytokines like IL-1ß, IL-6 or TNF-α from mononuclear cells of the peripheral 
blood and microglial cells from the central nervous system (CNS) [16,17]. Another effect of 
MSRV-Env mediated by TLR4 interaction is the blockade of oligodendrocyte differentiation, 
which is necessary for the remyelination process. Oligodendroglial precursor cells (OPCs) are 
present in the adult brain and can replace lost oligodendrocytes and remyelinate demyelinated 
axons and are therefore essential for the regeneration of the CNS [18]. This blockade of OPC
Part II Introduction 
78 
maturation by env could be influenced in vitro by an antibody targeted against env [19]. Both the 
pro-inflammatory effect and the direct toxicity on OPCs point to MSRV-Env as a relevant 
therapeutic target for MS.  
Based on these considerations, a recombinant humanised monoclonal antibody (mAb) of the 
IgG4/kappa class was designed to target the MSRV-Env [20]. This mAb, GNbAC1, selectively 
binds with high affinity to the surface domain of the MSRV-Env and neutralizes its TLR4 binding 
potential without interacting with this receptor [17,20]. As a consequence, GNbAC1 is expected 
to neutralize the effects of MSRV-Env in MS plaques and on circulating monocytes, and 
suppress its inflammatory and neurodegenerative potential [21]. In contrast to most of the 
monoclonal antibodies developed for the treatment of MS, which have been designed to interact 
with molecules and cells involved in the immune response [22], GNbAC1 targets a potential key 
factor in the disease without the need to modulate or suppress the immune system [23]. 
GNbAC1 is currently being developed as a potential first line therapy for MS, with a particular 
application for progressive forms of the disease [24]. The first-in-man clinical study with single 
doses up to 6 milligrams per kilogram of body weight was administered intravenously in 33 
young healthy volunteers [20]. In a subsequent study, GNbAC1 was tested in 10 MS patients in 
a randomized placebo controlled trial (Results I of part II of the presented work) with a one year 
open label extension [25,26] . 
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Aim of the Thesis 
We aimed to monitor in a phase 2a study the systemic immune response of patients with MS 
under treatment with GNbAC1, a monoclonal antibody targeting the envelope protein of the 
multiple sclerosis associated retrovirus. We analyzed the composition of immune cell subsets 
and the activation level of monocytes by flow cytometry and the response against viral and 
vaccine antigens by ELISpot.  
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Results 
I. Immunologic monitoring during a phase 2a trial oft he GNbAC1 antibody in 
patients with MS. 
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Immunologic monitoring during a phase
2a trial of the GNbAC1 antibody in
patients with MS
ABSTRACT
Objective: To monitor the systemic immune responses of patients with multiple sclerosis (MS)
under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS-
associated retrovirus, during a phase 2a trial.
Methods: We analyzed the composition of immune cell subsets and the activation level of mono-
cytes by flow cytometry and the response against viral and vaccine antigens by ELISpot.
Results: None of the endpoints measured revealed any immunosuppressive effect of the therapeu-
tic antibody. Activation of monocytes slightly decreased during treatment as predicted by the
hypothesized mechanism of action of GNbAC1.
Conclusion: These results support the conclusion that the antibody is safe for use in patients
with MS.
Classification of evidence: This study provides Class III evidence that in patients with MS GNbAC1
does not significantly affect several biomarkers of systemic immune response. Neurol
Neuroimmunol Neuroinflamm 2015;2:e144; doi: 10.1212/NXI.0000000000000144
GLOSSARY
CPT 5 cell preparation tube; env 5 envelope protein of MSRV; IFN 5 interferon; LPS 5 lipopolysaccharide; MAPK 5 mito-
gen-activated protein kinase; MBP 5 myelin basic protein; MS 5 multiple sclerosis; MSRV 5 MS-associated retrovirus;
TLR4 5 toll-like receptor 4.
Both genetic and environmental factors have been discussed in the pathogenesis of multiple
sclerosis (MS). Endogenous retroviruses fall between genetics and environment, having been
integrated into the human genome long ago and now being inherited like other genes.
Several studies indicate that an endogenous retrovirus, the MS-associated retrovirus
(MSRV), might be connected to MS pathogenesis. MSRV has been isolated from brain tis-
sue of patients with MS.1 Subsequently, different studies found increased viral copy numbers
and/or transcripts in blood, CSF, or brains of patients with MS compared with controls.2–4
Detection of MSRV was also correlated with disease severity and disability progression.5,6
MSRV might influence the pathogenesis of MS in 2 different ways: by targeting immune
cells and by interacting with oligodendrocytes. It has been shown that the envelope protein
of MSRV (env) can act as a ligand of toll-like receptor 4 (TLR4) and can activate cells
expressing this receptor, such as monocytes, leading to an aberrant upregulation of immune
reactivity, thus contributing to autoimmune pathology.7 It has also been suggested that env
might directly compromise oligodendrocytes, possibly also via interaction with TLR4.8,9 It
was therefore speculated that blocking the interaction between env and immune cells and/or
oligodendrocytes might be a novel therapeutic option in MS. Recently, results were reported
from a phase 2a trial of GNbAC1, a humanized monoclonal IgG4/k antibody against the
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extracellular domain of env.10 This trial
showed a favorable safety and pharmacoki-
netic profile of the therapeutic antibody and
showed that MSRV transcripts declined
during GNbAC1 treatment, indicating a
pharmacodynamic effect. The immunologic
substudy reported here examined blood sam-
ples from patients enrolled in the previously
published phase 2a trial to assess the impact
of the therapeutic antibody on the immune
system. Additional healthy volunteers were
recruited for comparison.
METHODS Patients and design. Blood samples were taken
from the 10 patients involved in the phase 2a trial (5 from Basel, 5
from Geneva) and from 5 healthy volunteers recruited addition-
ally for this immunologic substudy. Demographic details are pro-
vided in theT1 table. Patients received monthly infusions of 2 or 6
mg/kg body weight over a period of 6 months. Blood was drawn
on the day before the first administration of GNbAC1, on the
first day after administration, 2 weeks after administration, and at
the end of the 6-month treatment period. Two patients received
placebo for the first time point. Blood from healthy controls was
drawn at each time point on the same day as the patients and
processed in parallel. A schematic of the study design is shown in
figure e-1 at Neurology.org/nn.
Standard protocol approvals, registrations, and patient
consents. The study protocol was approved by the ethics com-
mittees of both centers and the Swiss Medicine Agency, Swiss-
medic. All patients enrolled in this study gave written informed
consent.
Assays. Blood taken from patients in Basel was processed
immediately. In Geneva, blood was drawn into cell preparation
tubes (CPTs), transported to Basel by courier, and processed
the same day. The primary research question was: How does
the state of the immune system change following treatment
with GNbAC1? This was addressed in 3 assays (Class III level
of evidence): (1) proportions of various immune cell popula-
tions by flow cytometry to monitor the general state of the
immune system; (2) interferon (IFN)-g production in response
to various antigens, using the Ready-SET-go human IFN-g
ELISpot kit (eBioscience, San Diego, CA) to measure
physiologic immune reactivity; and (3) p38 mitogen-activated
protein kinase (MAPK) phosphorylation by phospho-specific
flow cytometry (clone 36/p38, BD Biosciences, San Jose, CA)
as a measure of TLR4 stimulation in monocytes. Immune cell
subpopulations and ELISpot results are not reported from the
Geneva patients, whose peripheral blood mononuclear cells
after retrieval from CPTs contained variable levels of
erythrocytes, granulocytes, and other cell types, making
comparisons unreliable. For the p38 MAPK phosphorylation,
this problem was obviated by restricting flow cytometry to
CD33-positive monocytes, and results are reported for all 10
patients and 4 controls.
RESULTS Using flow cytometry, we determined the
frequencies of the main subfractions of lymphocytes
during the trial. We could not detect a difference in
the proportions of CD41 and CD81 T cells, B cells,
and monocytes between patients and controls. There
was also no change in the composition of lympho-
cytes during 6 months of treatment with GNbAC1
( F1figure 1A).
We monitored antigen-specific responses by
IFN-g ELISpot. We detected robust immune re-
sponses against varicella-zoster virus and tetanus
vaccine (Tetanol) throughout the study. The re-
sponses were highly variable between individuals
and across time but not obviously different
between patients and controls (figure 1B). The
presence of robust antivaccine and antiviral re-
sponses and the absence of antigen-independent
IFN-g production before and after treatment sug-
gest that there was no adverse activation or suppres-
sion of the protective immune response. We also
tested the T cell response against an established
autoantigen in MS, myelin basic protein (MBP).
The response against MBP was low in patients
and healthy controls and did not significantly
change over time (data not shown).
To monitor TLR4 activation in monocytes, we
determined the phosphorylation of p38, a key com-
ponent of the signaling pathway downstream of
TLR4, using a phospho-specific anti–p38 MAPK
antibody in flow cytometry. We were able to detect
the effect of lipopolysaccharide (LPS) down to 100
pg/mL (figure 1D), a level of sensitivity comparable
to the gold standard Limulus amebocyte lysate
endotoxin test. Primarily, we examined phospho-
rylation of p38 in naive monocytes (without
exogenous LPS) before and during treatment. The
pattern we observed was consistent with the
hypothesis underlying the proposed mechanism of
action of GNbAC1, i.e., before the trial, p38
phosphorylation was higher in patients with MS
than in healthy controls, and treatment reduced
the p38 phosphorylation in patients (figure 1C).
However, this did not reach statistical significance.
Table Patient and control demographic
characteristics
Characteristic Patients (N 5 10) Controls (N 5 5)
Age, y, mean 6 SD 53.4 6 6.6 37.6 6 8.2
Female/male 3/7 2/3
Diagnosis, n (%)
RRMS 1 (10.0) NA
PPMS 3 (30.0) NA
SPMS 6 (60.0) NA
EDSS, mean 6 SD 4.8 6 1.5 NA
Abbreviations: EDSS 5 Expanded Disability Status Scale;
NA 5 not applicable; PPMS 5 primary progressive multiple
sclerosis; RRMS 5 relapsing-remitting multiple sclerosis;
SPMS 5 secondary progressive multiple sclerosis.
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We also tracked p38 phosphorylation across
the trial in naive monocytes and in response to
various doses of LPS and observed that the response
to this exogenous TLR4 ligand was similar between
patients and controls and stable across the trial
(figure 1D).
Figure 1 Comparison of immune phenotype, antigen reactivity, and monocyte activation in blood of patients
and controls
(A) Cellular composition of peripheral blood mononuclear cells (PBMC) from 5 patients and 4 controls over time (immediately
before first infusion: D1, the following day: D2, 2 weeks later: D15, and the conclusion of the study: End). Percentages of
CD81 T cells, CD41 T cells, CD331 monocytes, and CD191 B cells in patients (black circles and lines) and controls (purple
squares and purple lines) at the 4 time points. Results are only reported fromBasel patients. Missing data points are indicated by
omitted symbols. (B) Interferon (IFN)-g response to a vaccine (Tetanol) and a viral antigen (varicella-zoster virus [VZV], Varilrix)
throughout the trial in 5 patients and 4 controls. Each condition was assayed in triplicate wells with PBMC exposed to the
stimulus using the human IFN-g ELISpot Ready-SET-Go! (eBioscience, San Diego, CA), and this figure displays the medians from
these triplicates at each time point for each of 5 patients and 4 controls. Results are only reported from Basel patients. Missing
data points are indicated by omitted symbols. (C) Phosphorylation of p38mitogen-activated protein kinase (MAPK) in monocytes
from 10 patients before and during treatment and from 5 healthy controls at the same time points. Cryopreserved PBMCwere
permeabilized in methanol and then immunolabeled with anti-CD33 antibodies (eBioscience) to identify monocytes and anti–
phospho-p38 MAPK antibodies (BD Biosciences, San Jose, CA) to measure phosphorylation. Vertical axis shows relative
phospho-p38 immunofluorescence (arbitrary units). When values from more than 1 time point were available before or during
the treatment period, these were averaged, producing 1 before-treatment and 1 during-treatment value for each patient. Time
points at which patients were given placebo were included in the pretreatment condition. Error bars show SEM. Averaging for
controls followed the patients to whom they were yoked, and the data were analyzed by repeated-measures 2-way analysis of
variance comparing effects of group (i.e., patients vs controls) and time point (i.e., before vs during treatment). Neither the main
effects nor the interactionwere significant. Since the parameter ofmost interestwas the comparison between beforeandduring
treatment within the patients, these data were also compared using a paired 2-tailed t test (p5 0.0671). (D) Phosphorylation of
p38MAPK inmonocytes of10patients and5 controls across the trial in response to lipopolysaccharide (LPS). Vertical axis is the
median immunofluorescence in arbitrary units. Purple lines and squares represent healthy untreated controls. Black lines and
circles represent patients. Each of the 4 panels shows results from1 time point fromblood exposed to a range of concentrations
of LPS, as indicated. The effect of dose was analyzed by linear regression and found to be significant (p , 0.0005 for both
patients and controls at each time point). This effect of dose (i.e., the slope of the dose-response regression lines) was compared
between patients and controls and between time points, but neither the main effects nor the interaction were significant.
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DISCUSSION These results are consistent with the
previously published report of the phase 2a trial in
that no evidence was obtained that GNbAC1 admin-
istration interferes with the normal functioning of the
immune system. This apparent evidence of safety
should be interpreted in light of the small size and
limited duration of the trial. Flow cytometry of
phospho-p38 in monocytes has potential as a
biomarker for monitoring response to treatment
with this antibody or any other agent targeting the
TLR signaling system. Larger studies will be
required to corroborate these findings and elucidate
the relationship between monocyte activation and
clinical response.
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Outlook 
Preclinical and early clinical data support the conclusion that GNbAC1, a recombinant, 
humanized, IgG4 monoclonal antibody directed against the MSRV-Env, presents a favorable 
safety profile, which is critical for long-term treatments. Recently, GeNeuro SA, the company that 
developed GNbAC1, announced that it has initiated its planned phase 2b study with GNbAC1 in 
relapsing-remitting MS (clinicaltrials.gov identifier NCT02782858). The study plans to recruit 260 
patients from 68 clinical centers in the European Union and Eastern Europe and expects 
preliminary results by the end of 2017. Considering our results monitoring of the phosphorylation 
of p38 in monocytes might be a possible biomarker that reflects the mode of action of GNbAC1. 
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